515c57571f
Cuts the initial bundle roughly in half. Users who open Home,
Extensions, or FAQ download ~343 kB / 106 kB gz instead of 817 kB /
230 kB gz. Heavy clinical reference data (PE_DATA, Fenton LMS,
Rosner BP splines, 15 Bedside drug panels, 10 Calculator formulas,
13 Settings sub-sections, 10 Admin sub-tabs) only loads when the
user opens that route.
client/src/App.tsx
Every route except Home / Extensions / FAQ wrapped in
React.lazy(() => import(...)) + <Suspense fallback>. Extensions and
FAQ stay in the main chunk because they're small (3 kB, 2 kB) and
likely visited early. The RouteFallback component shows a single
"Loading…" line — Vite prefetches chunks on hover so the delay is
typically invisible.
Resulting chunks (gzipped):
• index.js 106 kB React + Router + Query + Layout +
Home + Extensions + FAQ
• Bedside.js 33 kB 15 clinical dosing panels
• PeGuide.js 36 kB PE_DATA hierarchy + scales + sounds
• Calculators.js 42 kB All 10 calculators + BP Rosner
coefficients + Fenton + BMI LMS
• Settings.js 10 kB 13 Settings sub-sections
• Admin.js 7 kB 10 Admin sub-tabs
• Learning.js 3 kB
• Fenton chunk (shared) 3 kB Reused between Bedside neonatal
and the Growth Charts calculator
• Note pages (each) 1-2 kB Encounter / SOAP / Well / Sick /
Hospital / Chart / Dictation / Vax /
Catch-up individually chunked
Vite's 500 kB chunk-size warning is gone. No functional changes.
1 line
No EOL
131 KiB
JavaScript
1 line
No EOL
131 KiB
JavaScript
import{i as e,n as t,t as n}from"./jsx-runtime-ByY1xr43.js";import{c as r,d as i,i as a,l as o,u as s}from"./fenton-9EKyvVkL.js";var c=e(t(),1),l=n(),u=`rounded-lg border border-border bg-card p-5 space-y-3`,d=`w-full rounded-md border border-input bg-background px-3 py-2 text-sm outline-none focus:ring-2 focus:ring-ring`,f=`block text-xs font-medium text-muted-foreground`,p=`text-left px-2 py-1.5 border-b border-border font-semibold uppercase tracking-wide text-[10px] text-muted-foreground`,m=`px-2 py-1.5 border-b border-border align-top text-sm`;function h({label:e}){let t=e.indexOf(`(`);return t<0?(0,l.jsx)(`span`,{className:`font-semibold`,children:e}):(0,l.jsxs)(`span`,{children:[(0,l.jsx)(`span`,{className:`font-semibold`,children:e.slice(0,t).trim()}),` `,(0,l.jsx)(`span`,{className:`text-xs text-muted-foreground`,children:e.slice(t)})]})}function g({children:e,notes:t=!0}){return(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:p,children:`Drug`}),(0,l.jsx)(`th`,{className:p,children:`Dose`}),(0,l.jsx)(`th`,{className:p,children:`Route`}),t&&(0,l.jsx)(`th`,{className:p,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:e})]})})}function _({name:e,dose:t,route:n,notes:r}){return(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:m+` font-semibold`,dangerouslySetInnerHTML:{__html:e}}),(0,l.jsx)(`td`,{className:m,children:t}),(0,l.jsx)(`td`,{className:m+` text-xs`,children:n}),r!==void 0&&(0,l.jsx)(`td`,{className:m+` text-xs text-muted-foreground`,dangerouslySetInnerHTML:{__html:r}})]})}function v(){let[e,t]=(0,c.useState)(``),[n,r]=(0,c.useState)(`0`),[i,o]=(0,c.useState)(``),[s,p]=(0,c.useState)(`male`),[m,v]=(0,c.useState)(``),[y,b]=(0,c.useState)({appearance:2,pulse:2,grimace:2,activity:2,respiration:2}),x=Number.parseInt(e,10),S=Number.parseInt(n,10)||0,C=Number.parseFloat(i),w=Number.isFinite(x)&&x>=22&&x<=44&&Number.isFinite(C)&&C>0?a(x,S,C,s):null,T=Number.parseFloat(m),E=Number.isFinite(T)&&T>0,D=E?Math.round(T*.01*100)/100:0,O=E?Math.round(T*.03*100)/100:0,k=E?Math.round(T*.05*100)/100:0,A=E?Math.round(T*.1*100)/100:0,j=E?Math.round(T*10):0,M=E?Math.round(T*2*10)/10:0,N=Object.values(y).reduce((e,t)=>e+t,0),P=N>=7?`Reassuring`:N>=4?`Moderately depressed`:`Severely depressed`,F=N>=7?`text-green-600 bg-green-50`:N>=4?`text-amber-600 bg-amber-50`:`text-destructive bg-red-50`,I=N>=7?`Routine newborn care. Continue reassessment. Repeat at 5 min.`:N>=4?`Stimulate, clear airway, warm. Give O₂ if cyanotic. Ventilate with PPV if HR <100 or apneic/gasping. Reassess q30 sec.`:`Full NRP pathway — PPV immediately. Intubate if PPV ineffective. Chest compressions if HR <60. Epinephrine and volume per NRP.`;return(0,l.jsxs)(`section`,{className:u,"data-testid":`bedside-panel-neonatal`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Neonatal Assessment + NRP + Apgar`}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold`,children:`Gestational age + size assessment (Fenton 2013)`}),(0,l.jsxs)(`div`,{className:`grid gap-2 grid-cols-2 sm:grid-cols-4 max-w-xl`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`GA weeks`}),(0,l.jsx)(`input`,{type:`number`,min:`22`,max:`44`,className:d,value:e,onChange:e=>t(e.target.value),"data-testid":`neo-weeks`})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`GA days (0-6)`}),(0,l.jsx)(`input`,{type:`number`,min:`0`,max:`6`,className:d,value:n,onChange:e=>r(e.target.value),"data-testid":`neo-days`})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Birth wt (g)`}),(0,l.jsx)(`input`,{type:`number`,min:`200`,max:`7000`,className:d,value:i,onChange:e=>o(e.target.value),"data-testid":`neo-weight`})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Sex`}),(0,l.jsxs)(`select`,{className:d,value:s,onChange:e=>p(e.target.value),"data-testid":`neo-sex`,children:[(0,l.jsx)(`option`,{value:`male`,children:`Male`}),(0,l.jsx)(`option`,{value:`female`,children:`Female`})]})]})]}),w&&(0,l.jsxs)(`div`,{className:`grid gap-3 sm:grid-cols-2`,"data-testid":`neo-result`,children:[(0,l.jsxs)(`div`,{className:`rounded-md border p-3`,style:{borderColor:w.gaClass.color+`55`,background:w.gaClass.color+`10`},children:[(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`Gestational Age`}),(0,l.jsx)(`div`,{className:`text-base font-bold`,style:{color:w.gaClass.color},children:w.gaClass.label}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[x,` wk `,S,` d (`,w.gaDecimal.toFixed(1),` wk)`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border p-3`,style:{borderColor:w.weightClass.color+`55`,background:w.weightClass.color+`10`},children:[(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`Weight for Gestational Age`}),(0,l.jsx)(`div`,{className:`text-base font-bold`,style:{color:w.weightClass.color},children:w.weightClass.label}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[w.percentile.toFixed(1),`th percentile · `,w.weightClass.detail]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border p-3`,style:{borderColor:w.bwClass.color+`55`,background:w.bwClass.color+`10`},children:[(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`Birth Weight Category`}),(0,l.jsx)(`div`,{className:`text-base font-bold`,style:{color:w.bwClass.color},children:w.bwClass.label}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[C,` g (`,(C/1e3).toFixed(2),` kg)`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border border-border bg-muted/40 p-3 text-xs`,children:[(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground uppercase tracking-wide`,children:[`Fenton (`,s,`)`]}),(0,l.jsxs)(`div`,{className:`space-y-0.5 mt-1`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Expected weight (M):`}),` `,w.expectedWeight,` g`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Z-score:`}),` `,w.z.toFixed(2)]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Percentile:`}),` `,w.percentile.toFixed(1),`%`]})]})]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`NRP pathway (AHA/AAP 8th ed 2020)`}),(0,l.jsxs)(`div`,{className:`space-y-2 text-sm`,children:[(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`BIRTH — ASSESS (first 30 sec)`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`Term? Tone? Breathing/crying? All yes → routine care. Any no → warm, dry, stimulate, clear airway PRN, evaluate HR + resp.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-purple-500 bg-purple-50 dark:bg-purple-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`HR <100 OR apneic/gasping (60 s)`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[(0,l.jsx)(`strong`,{children:`Start PPV`}),` 40-60 breaths/min, room air for term / 21-30% for preterm. Attach SpO₂ (right hand) ± ECG. MR SOPA if ineffective.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-amber-500 bg-amber-50 dark:bg-amber-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`HR <100 after 30 s effective PPV`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`Reassess ventilation — ensure chest rise. Consider increasing FiO₂, intubation, or LMA. Continue PPV.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-red-500 bg-red-50 dark:bg-red-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`HR <60 after 30 s effective PPV`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[(0,l.jsx)(`strong`,{children:`Intubate + chest compressions`}),` — 3:1 ratio (90 compressions + 30 breaths/min), FiO₂ 100%, lower 1/3 sternum, depth 1/3 AP chest.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-destructive bg-red-100 dark:bg-red-950/40 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`HR <60 despite compressions + PPV × 60 s`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[(0,l.jsx)(`strong`,{children:`Epinephrine 1:10,000 (0.1 mg/mL):`}),` IV/IO 0.01-0.03 mg/kg (0.1-0.3 mL/kg) — preferred. ETT 0.05-0.1 mg/kg. Repeat q3-5 min. Hypovolemia: `,(0,l.jsx)(`strong`,{children:`NS 10 mL/kg IV/IO over 5-10 min`}),`.`]})]})]}),(0,l.jsxs)(`div`,{className:`grid grid-cols-1 sm:grid-cols-3 gap-2 text-xs`,children:[(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-2`,children:[(0,l.jsx)(`strong`,{children:`Target SpO₂ (preductal):`}),(0,l.jsx)(`br`,{}),`1 min 60-65% · 2 min 65-70% · 3 min 70-75% · 4 min 75-80% · 5 min 80-85% · 10 min 85-95%`]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-2`,children:[(0,l.jsx)(`strong`,{children:`Initial ETT size:`}),(0,l.jsx)(`br`,{}),`<1 kg / <28 wk: 2.5 · 1-2 kg / 28-34 wk: 3.0 · 2-3 kg / 34-38 wk: 3.5 · >3 kg / >38 wk: 3.5-4.0`]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-2`,children:[(0,l.jsx)(`strong`,{children:`ETT depth (lip):`}),` ~6 + weight(kg) cm`]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`NRP drug doses`}),(0,l.jsxs)(`div`,{className:`max-w-xs`,children:[(0,l.jsx)(`label`,{className:f,children:`Weight (kg)`}),(0,l.jsx)(`input`,{type:`number`,min:`0.3`,step:`0.1`,className:d,value:m,onChange:e=>v(e.target.value),"data-testid":`nrp-weight`})]}),E?(0,l.jsxs)(g,{children:[(0,l.jsx)(_,{name:`Epinephrine 1:10,000`,dose:(0,l.jsx)(h,{label:`${D}-${O} mg, ${Math.round(D*10)/10}-${Math.round(O*10)/10} mL (0.01-0.03 mg/kg = 0.1-0.3 mL/kg)`}),route:`IV / IO`,notes:`Preferred route. Repeat q3-5 min.`}),(0,l.jsx)(_,{name:`Epinephrine 1:10,000`,dose:(0,l.jsx)(h,{label:`${k}-${A} mg, ${Math.round(k*10)/10}-${Math.round(A*10)/10} mL (0.05-0.1 mg/kg = 0.5-1 mL/kg)`}),route:`ETT`,notes:`While IV being placed.`}),(0,l.jsx)(_,{name:`Normal saline`,dose:(0,l.jsx)(h,{label:`${j} mL (10 mL/kg)`}),route:`IV / IO`,notes:`Over 5-10 min for volume. Repeat PRN.`}),(0,l.jsx)(_,{name:`Dextrose 10%`,dose:(0,l.jsx)(h,{label:`${M} mL (2 mL/kg = 0.2 g/kg)`}),route:`IV slow push`,notes:`For documented hypoglycemia. Then D10 infusion 4-6 mg/kg/min.`})]}):(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see NRP doses.`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Concentration note:`}),` NRP uses epinephrine `,(0,l.jsx)(`strong`,{children:`1:10,000`}),` (0.1 mg/mL). NOT 1:1000 (1 mg/mL) — that is IM for anaphylaxis / older patients.`]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`Apgar score`}),(0,l.jsx)(`div`,{className:`grid gap-2 grid-cols-1 sm:grid-cols-5 text-xs`,children:[[`appearance`,`Appearance`,[`Blue/pale`,`Body pink, extremities blue`,`All pink`]],[`pulse`,`Pulse`,[`Absent`,`<100 bpm`,`≥100 bpm`]],[`grimace`,`Grimace`,[`No response`,`Grimace`,`Cough/sneeze`]],[`activity`,`Activity`,[`Limp`,`Some flexion`,`Active motion`]],[`respiration`,`Respiration`,[`Absent`,`Slow/irregular`,`Good/crying`]]].map(([e,t,n])=>(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:t}),(0,l.jsx)(`select`,{className:d,value:y[e],onChange:t=>b({...y,[e]:Number(t.target.value)}),"data-testid":`apgar-`+e,children:n.map((e,t)=>(0,l.jsxs)(`option`,{value:t,children:[t,` — `,e]},t))})]},e))}),(0,l.jsxs)(`div`,{className:`rounded-md p-3 `+F,"data-testid":`apgar-result`,children:[(0,l.jsxs)(`div`,{className:`text-base font-bold`,children:[`Apgar: `,N,`/10 — `,P]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:I})]}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground italic`,children:[`Fenton TR, Kim JH. BMC Pediatr 2013;13:59 · NRP 8th ed (AHA/AAP 2020) · Apgar is a description of status — `,(0,l.jsx)(`strong`,{children:`never`}),` delay resuscitation while scoring.`]})]})}function y(){let[e,t]=(0,c.useState)(`asthma`),[n,r]=(0,c.useState)(``),i=Number.parseFloat(n),a=Number.isFinite(i)&&i>0,o=(e,t,n=`mg`)=>a?s(i,e,t,n):null,[p,m]=(0,c.useState)(null),[v,y]=(0,c.useState)({spo2:0,retractions:0,scalene:0,air:0,wheeze:0}),b=Object.values(v).reduce((e,t)=>e+t,0),x=b<=3?`Mild`:b<=7?`Moderate`:`Severe`,S=b<=3?`text-green-600 bg-green-50`:b<=7?`text-amber-600 bg-amber-50`:`text-destructive bg-red-50`,[C,w]=(0,c.useState)({conscious:0,cyanosis:0,stridor:0,air:0,retractions:0}),T=Object.values(C).reduce((e,t)=>e+t,0),E=T<=2?`Mild`:T<=5?`Moderate`:T<=11?`Severe`:`Impending Respiratory Failure`,D=T<=2?`text-green-600 bg-green-50`:T<=5?`text-amber-600 bg-amber-50`:T<=11?`text-destructive bg-red-50`:`text-red-900 bg-red-100`,[O,k]=(0,c.useState)({age:`gte12w`,spo2:`ok`,hydration:`ok`,distress:`mild`}),A=O.distress===`severe`||O.spo2===`low`||O.hydration===`poor`||O.age===`lt12w`;return(0,l.jsxs)(`section`,{className:u,"data-testid":`bedside-panel-respiratory`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Respiratory`}),(0,l.jsx)(`div`,{className:`flex gap-2 flex-wrap`,children:[`asthma`,`pram`,`croup`,`bronch`].map(n=>(0,l.jsx)(`button`,{type:`button`,onClick:()=>t(n),className:`px-3 py-1 rounded-full text-xs font-medium border `+(e===n?`bg-primary text-primary-foreground border-primary`:`bg-muted border-border`),"data-testid":`resp-mode-`+n,children:n===`asthma`?`Asthma`:n===`pram`?`PRAM`:n===`croup`?`Croup (Westley)`:`Bronchiolitis`},n))}),e!==`pram`&&e!==`bronch`&&(0,l.jsxs)(`div`,{className:`max-w-xs`,children:[(0,l.jsx)(`label`,{className:f,children:`Weight (kg)`}),(0,l.jsx)(`input`,{type:`number`,min:`0.3`,step:`0.1`,className:d,value:n,onChange:e=>r(e.target.value),"data-testid":`resp-weight`})]}),e===`asthma`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`div`,{className:`flex gap-2`,children:[`mild`,`moderate`,`severe`].map(e=>(0,l.jsx)(`button`,{type:`button`,onClick:()=>m(e),className:`px-3 py-1 rounded text-xs font-medium border `+(p===e?e===`mild`?`bg-green-600 text-white`:e===`moderate`?`bg-amber-500 text-white`:`bg-destructive text-white`:`bg-muted`),children:e.charAt(0).toUpperCase()+e.slice(1)},e))}),p&&!a&&(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see doses.`}),p===`mild`&&a&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`p`,{className:`text-xs text-muted-foreground`,children:`Speaks in sentences, no accessory muscle use, SpO₂ ≥94%`}),(0,l.jsxs)(g,{children:[(0,l.jsx)(_,{name:`Albuterol (MDI)`,dose:`4-8 puffs via spacer`,route:`Inhaled`,notes:`q20min × 3 doses, then q1-4h`}),(0,l.jsx)(_,{name:`Albuterol (neb)`,dose:(0,l.jsx)(h,{label:`${o(.15,5,`mg`).label} (min 2.5 mg)`}),route:`Nebulized`,notes:`q20min × 3 doses`}),(0,l.jsx)(_,{name:`Dexamethasone`,dose:(0,l.jsx)(h,{label:o(.6,16).label}),route:`PO/IV`,notes:`Single dose, or 2 days`}),(0,l.jsx)(_,{name:`Prednisolone`,dose:(0,l.jsx)(h,{label:`${o(1,60).label}/day`}),route:`PO`,notes:`Alternative: 3-5 day course`})]})]}),p===`moderate`&&a&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`p`,{className:`text-xs text-muted-foreground`,children:`Speaks in phrases, some accessory muscle use, SpO₂ 90-93%`}),(0,l.jsxs)(g,{children:[(0,l.jsx)(_,{name:`Albuterol (neb)`,dose:(0,l.jsx)(h,{label:`${o(.15,5,`mg`).label} (min 2.5 mg)`}),route:`Nebulized`,notes:`q20min × 3 doses, then continuous if needed`}),(0,l.jsx)(_,{name:`Ipratropium`,dose:i<20?`250 mcg`:`500 mcg`,route:`Nebulized`,notes:`q20min × 3 doses with albuterol`}),(0,l.jsx)(_,{name:`Dexamethasone`,dose:(0,l.jsx)(h,{label:o(.6,16).label}),route:`PO/IV/IM`,notes:`Single dose`}),(0,l.jsx)(_,{name:`O₂ supplemental`,dose:`Target SpO₂ ≥94%`,route:`NC/mask`,notes:`Titrate to effect`})]})]}),p===`severe`&&a&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`p`,{className:`text-xs text-muted-foreground`,children:`Speaks in words only, significant accessory muscle use, SpO₂ <90%. Consider ICU.`}),(0,l.jsxs)(g,{children:[(0,l.jsx)(_,{name:`Albuterol continuous`,dose:(0,l.jsx)(h,{label:`${o(.5,20,`mg`).label}/hr`}),route:`Continuous neb`,notes:`Or 0.15-0.3 mg/kg q20min`}),(0,l.jsx)(_,{name:`Ipratropium`,dose:i<20?`250 mcg`:`500 mcg`,route:`Nebulized`,notes:`q20min × 3 doses with albuterol`}),(0,l.jsx)(_,{name:`Dexamethasone`,dose:(0,l.jsx)(h,{label:o(.6,16).label}),route:`IV`,notes:`Or methylprednisolone 2 mg/kg IV (max 60 mg)`}),(0,l.jsx)(_,{name:`Magnesium sulfate`,dose:(0,l.jsx)(h,{label:`${o(50,2e3).label} IV over 20 min`}),route:`IV`,notes:`Single dose, monitor BP`}),(0,l.jsx)(_,{name:`Epinephrine (IM)`,dose:(0,l.jsx)(h,{label:`${o(.01,.5).label} (1:1000)`}),route:`IM`,notes:`If impending arrest / no IV access`}),(0,l.jsx)(_,{name:`Terbutaline`,dose:(0,l.jsx)(h,{label:`${o(.01,.4).label} SC/IV`}),route:`SC/IV`,notes:`Then 0.1-10 mcg/kg/min infusion`}),(0,l.jsx)(_,{name:`O₂ supplemental`,dose:`Target SpO₂ ≥94%`,route:`High flow / NIPPV`,notes:`Consider BiPAP/CPAP`})]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-red-50 dark:bg-red-950/30 p-3 text-xs text-red-900 dark:text-red-100`,children:[(0,l.jsx)(`strong`,{children:`Continuous monitoring.`}),` Consider ICU admission. If no response to magnesium → terbutaline infusion. If impending respiratory failure → intubation (ketamine preferred induction agent).`]})]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`NAEPP/GINA guidelines. Always use clinical judgment.`})]}),e===`pram`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`p`,{className:`text-sm text-muted-foreground`,children:`Pediatric Respiratory Assessment Measure (PRAM) — for asthma exacerbation severity (0-12).`}),(0,l.jsx)(`div`,{className:`grid gap-2 grid-cols-1 sm:grid-cols-2`,children:[[`spo2`,`SpO₂`,[`≥95% (0)`,`92-94% (1)`,`<92% (2)`]],[`retractions`,`Suprasternal retractions`,[`Absent (0)`,`Present (2)`]],[`scalene`,`Scalene muscle use`,[`Absent (0)`,`Present (2)`]],[`air`,`Air entry`,[`Normal (0)`,`Mild ↓ at bases (1)`,`Widespread ↓ (2)`,`Absent/minimal (3)`]],[`wheeze`,`Wheezing`,[`Absent (0)`,`Expiratory only (1)`,`Ins+exp (2)`,`Audible without stethoscope/silent chest (3)`]]].map(([e,t,n])=>(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:t}),(0,l.jsx)(`select`,{className:d,value:v[e],onChange:t=>y({...v,[e]:Number(t.target.value)}),"data-testid":`pram-`+e,children:n.map((e,t)=>(0,l.jsx)(`option`,{value:t,children:e},t))})]},e))}),(0,l.jsxs)(`div`,{className:`rounded-md p-3 `+S,"data-testid":`pram-result`,children:[(0,l.jsxs)(`div`,{className:`text-base font-bold`,children:[`PRAM Score: `,b,`/12 — `,x]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Mild (0-3): outpatient management. Moderate (4-7): consider oral steroids + frequent bronchodilators. Severe (8-12): aggressive treatment, consider ICU.`})]})]}),e===`croup`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`p`,{className:`text-sm text-muted-foreground`,children:`Westley croup score (0-17).`}),(0,l.jsx)(`div`,{className:`grid gap-2 grid-cols-1 sm:grid-cols-2`,children:[[`conscious`,`Level of consciousness`,[`Normal (0)`,`Disoriented (5)`]],[`cyanosis`,`Cyanosis`,[`None (0)`,`With agitation (4)`,`At rest (5)`]],[`stridor`,`Stridor`,[`None (0)`,`With agitation (1)`,`At rest (2)`]],[`air`,`Air entry`,[`Normal (0)`,`Decreased (1)`,`Severely decreased (2)`]],[`retractions`,`Retractions`,[`None (0)`,`Mild (1)`,`Moderate (2)`,`Severe (3)`]]].map(([e,t,n])=>(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:t}),(0,l.jsx)(`select`,{className:d,value:C[e],onChange:t=>w({...C,[e]:Number(t.target.value)}),"data-testid":`croup-`+e,children:n.map((e,t)=>(0,l.jsx)(`option`,{value:t,children:e},t))})]},e))}),(0,l.jsxs)(`div`,{className:`rounded-md p-3 `+D,"data-testid":`croup-result`,children:[(0,l.jsxs)(`div`,{className:`text-base font-bold`,children:[`Westley: `,T,`/17 — `,E]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Mild ≤2 · Moderate 3-5 · Severe 6-11 · Impending failure ≥12.`})]}),a&&(0,l.jsxs)(g,{children:[(0,l.jsx)(_,{name:`Dexamethasone`,dose:(0,l.jsx)(h,{label:o(.6,16).label}),route:T<=2?`PO`:T<=5?`PO/IM`:`IV/IM`,notes:`Preferred corticosteroid; single dose`}),T>2&&(0,l.jsx)(_,{name:`Racemic epinephrine`,dose:`0.5 mL of 2.25% solution`,route:`Nebulized`,notes:`May repeat q15-20min, observe 2-4 h`}),T>2&&(0,l.jsx)(_,{name:`Nebulized epinephrine`,dose:`0.5 mL/kg of 1:1000 (max 5 mL)`,route:`Nebulized`,notes:`Alternative to racemic`}),T>5&&(0,l.jsx)(_,{name:`Heliox`,dose:`70:30 or 80:20`,route:`Face mask`,notes:`Consider if not responding`})]})]}),e===`bronch`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`grid gap-2 grid-cols-1 sm:grid-cols-2 max-w-xl`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Age`}),(0,l.jsxs)(`select`,{className:d,value:O.age,onChange:e=>k({...O,age:e.target.value}),children:[(0,l.jsx)(`option`,{value:`lt12w`,children:`<12 weeks (high risk)`}),(0,l.jsx)(`option`,{value:`gte12w`,children:`≥12 weeks`})]})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`SpO₂`}),(0,l.jsxs)(`select`,{className:d,value:O.spo2,onChange:e=>k({...O,spo2:e.target.value}),children:[(0,l.jsx)(`option`,{value:`ok`,children:`≥90%`}),(0,l.jsx)(`option`,{value:`low`,children:`<90%`})]})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Hydration`}),(0,l.jsxs)(`select`,{className:d,value:O.hydration,onChange:e=>k({...O,hydration:e.target.value}),children:[(0,l.jsx)(`option`,{value:`ok`,children:`Adequate`}),(0,l.jsx)(`option`,{value:`poor`,children:`Poor oral intake`})]})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Distress`}),(0,l.jsxs)(`select`,{className:d,value:O.distress,onChange:e=>k({...O,distress:e.target.value}),children:[(0,l.jsx)(`option`,{value:`mild`,children:`Mild`}),(0,l.jsx)(`option`,{value:`moderate`,children:`Moderate`}),(0,l.jsx)(`option`,{value:`severe`,children:`Severe`})]})]})]}),(0,l.jsxs)(`div`,{className:`rounded-md p-3 `+(A?`text-destructive bg-red-50`:`text-green-600 bg-green-50`),"data-testid":`bronch-result`,children:[(0,l.jsx)(`div`,{className:`text-base font-bold`,children:A?`Admit / Observe`:`Likely Safe for Discharge`}),O.age===`lt12w`&&(0,l.jsx)(`div`,{className:`text-xs text-destructive mt-1`,children:`⚠ Age <12 weeks — high risk for apnea. Monitor closely.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`NOT recommended (AAP 2014/2023):`}),` Albuterol/salbutamol (no benefit), epinephrine (no evidence), systemic corticosteroids (no benefit), antibiotics (unless bacterial co-infection), chest physiotherapy.`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`AAP Clinical Practice Guideline: Management of Bronchiolitis in Infants and Children (2014, reaffirmed 2023). RSV most common (50-80%).`})]})]})}function b(){let[e,t]=(0,c.useState)(``),[n,r]=(0,c.useState)(``),i=Number.parseFloat(e),a=Number.parseFloat(n),o=Number.isFinite(i)&&i>0,s=o?Math.round(i*1*10)/10:0,p=o?Math.round(i*2*10)/10:0,m=o?Math.round(i*6*10)/10:0,h=o?Math.round(i*8*10)/10:0,v=Number.isFinite(a)&&a>=0?a<.1?`30-40`:a<1?`25-35`:a<5?`20-25`:a<12?`16-20`:`12-16`:``;return(0,l.jsxs)(`section`,{className:u,"data-testid":`bedside-panel-ventilation`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`O₂ & Ventilation`}),(0,l.jsxs)(`div`,{className:`grid gap-2 grid-cols-2 max-w-md`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Weight (kg)`}),(0,l.jsx)(`input`,{type:`number`,min:`0.3`,step:`0.1`,className:d,value:e,onChange:e=>t(e.target.value),"data-testid":`vent-weight`})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Age (years)`}),(0,l.jsx)(`input`,{type:`number`,min:`0`,step:`0.5`,className:d,value:n,onChange:e=>r(e.target.value),"data-testid":`vent-age`})]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold`,children:`Target SpO₂`}),(0,l.jsxs)(g,{notes:!0,children:[(0,l.jsx)(_,{name:`Most children`,dose:`94-98%`,route:`—`,notes:`Normal`}),(0,l.jsx)(_,{name:`Bronchiolitis (AAP 2014/2023)`,dose:`≥90%`,route:`—`,notes:`Don't chase higher saturations`}),(0,l.jsx)(_,{name:`Chronic lung disease / CF`,dose:`90-94%`,route:`—`,notes:`Avoid hyperoxia in CO₂ retainers`}),(0,l.jsx)(_,{name:`Preterm neonate`,dose:`90-95%`,route:`—`,notes:`Minimize ROP risk`}),(0,l.jsx)(_,{name:`Term neonate (min of life)`,dose:`Per NRP ladder`,route:`—`,notes:`1 min 60-65% · 10 min 85-95%`})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`Escalation ladder`}),(0,l.jsxs)(`div`,{className:`space-y-2 text-sm`,children:[(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-green-500 bg-green-50 dark:bg-green-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`1. Nasal cannula (low-flow)`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[(0,l.jsx)(`strong`,{children:`0.5-6 L/min`}),` · FiO₂ ~24-40% · comfortable, no humidification. Good for mild hypoxia.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`2. Simple face mask`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[(0,l.jsx)(`strong`,{children:`6-10 L/min`}),` · FiO₂ 35-60%. Must keep flow >6 L/min to flush CO₂.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-purple-500 bg-purple-50 dark:bg-purple-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`3. Non-rebreather mask`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[(0,l.jsx)(`strong`,{children:`10-15 L/min`}),` · FiO₂ 60-90%. Reservoir bag must stay inflated.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-amber-500 bg-amber-50 dark:bg-amber-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`4. High-flow nasal cannula (HFNC)`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[(0,l.jsx)(`strong`,{children:o?`1-2 L/kg/min = ${s}-${p} L/min`:`1-2 L/kg/min`}),` · heated + humidified · FiO₂ 30-100% titratable · generates ~2-5 cmH₂O PEEP. Reassess at 1-2 h.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-red-500 bg-red-50 dark:bg-red-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`5. Non-invasive (CPAP / BiPAP)`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`CPAP 5-10 cmH₂O · BiPAP IPAP 10-14 / EPAP 5. Needs cooperative patient, intact airway reflexes, no copious secretions.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-destructive bg-red-100 dark:bg-red-950/40 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`6. Intubate + mechanical ventilation`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`When NIV fails, airway compromised, apnea, or GCS ≤8. See Airway tab for RSI drugs.`})]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`Bag-Valve-Mask (BVM)`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-xs space-y-1`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`When:`}),` apnea, bradycardia (HR <60 neonate; inadequate breathing at any age), during resuscitation.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Rate:`}),` Newborn 40-60/min · Infant-child 20-30/min · Adolescent 10-12/min (1 breath q5-6 sec).`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Tidal volume:`}),` 6-8 mL/kg — gentle chest rise only. Avoid over-ventilation.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Technique:`}),` head tilt / jaw thrust, E-C or 2-thumb mask seal, squeeze 1 sec, release fully.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Not ventilating?`}),` MR SOPA — Mask reseal, Reposition airway, Suction, Open mouth, Pressure ↑, Alternative airway.`]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`Mechanical vent — starting settings`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-xs space-y-1`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Mode:`}),` Volume-control OR Pressure-control. PRVC / SIMV-PS hybrids.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Tidal volume:`}),` `,(0,l.jsx)(`strong`,{children:o?`${m}-${h} mL`:`6-8 mL/kg`}),` (6-8 mL/kg). Use 4-6 mL/kg for ARDS.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Rate:`}),` `,v?`${v}/min (age ${a} yr)`:`Newborn 30-40 · Infant 25-35 · Child 16-20 · Adolescent 12-16`,`.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`PEEP:`}),` start 5 cmH₂O. Increase to 8-12+ for refractory hypoxia.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`FiO₂:`}),` start 100%, wean rapidly to lowest that maintains target SpO₂.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`I:E ratio:`}),` 1:2 normally; 1:3-4 for obstructive disease.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Plateau pressure:`}),` keep <30 cmH₂O (ideally <28).`]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`Adjusting for gas exchange`}),(0,l.jsxs)(g,{notes:!0,children:[(0,l.jsx)(_,{name:`Low SpO₂ (oxygenation)`,dose:`↑ FiO₂`,route:`—`,notes:`Then ↑ PEEP (recruits collapsed alveoli)`}),(0,l.jsx)(_,{name:`↑ PCO₂ (ventilation)`,dose:`↑ Rate`,route:`—`,notes:`Then ↑ Tidal volume`}),(0,l.jsx)(_,{name:`↓ PCO₂ (over-ventilating)`,dose:`↓ Rate`,route:`—`,notes:`Then ↓ Tidal volume`}),(0,l.jsx)(_,{name:`High peak pressure`,dose:`Check tube / compliance`,route:`—`,notes:`Suction, bronchodilator, lower TV`}),(0,l.jsx)(_,{name:`Auto-PEEP (asthma, bronch)`,dose:`↓ Rate, ↑ Te`,route:`—`,notes:`Disconnect + bag briefly if critical`})]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-green-50 dark:bg-green-950/30 p-3 text-xs text-green-900 dark:text-green-100`,children:[(0,l.jsx)(`strong`,{children:`Mental model:`}),` Oxygenation is mostly `,(0,l.jsx)(`strong`,{children:`FiO₂ + PEEP`}),`. Ventilation (CO₂) is mostly `,(0,l.jsx)(`strong`,{children:`rate + tidal volume`}),`. Obstructive (asthma, bronchiolitis) → long expiratory time, permissive hypercapnia. Restrictive (ARDS) → low TV, high PEEP, permissive hypercapnia + hypoxia.`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`AAP / PALS / AARC guidance.`})]})}function x(){let[e,t]=(0,c.useState)(``),[n,r]=(0,c.useState)(`child`),i=Number.parseFloat(e),a=Number.isFinite(i)&&i>0,o=(e,t,n=`mg`)=>a?s(i,e,t,n):null,p=n===`neonate`?`Neonate (0-28 d)`:n===`infant`?`Young infant (29 d - 3 mo)`:`Older child / adolescent`,m=a?Math.round(i*20):null;return(0,l.jsxs)(`section`,{className:u,"data-testid":`bedside-panel-sepsis`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Sepsis & Fever`}),(0,l.jsxs)(`div`,{className:`grid gap-2 grid-cols-1 sm:grid-cols-2 max-w-md`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Weight (kg)`}),(0,l.jsx)(`input`,{type:`number`,min:`0.3`,step:`0.1`,className:d,value:e,onChange:e=>t(e.target.value),"data-testid":`sepsis-weight`})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Age band`}),(0,l.jsxs)(`select`,{className:d,value:n,onChange:e=>r(e.target.value),"data-testid":`sepsis-age`,children:[(0,l.jsx)(`option`,{value:`neonate`,children:`Neonate (0-28 d)`}),(0,l.jsx)(`option`,{value:`infant`,children:`Infant (29 d - 3 mo)`}),(0,l.jsx)(`option`,{value:`child`,children:`Older child / adolescent`})]})]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-destructive bg-red-50 dark:bg-red-950/30 p-3 text-sm font-semibold text-destructive`,children:[`Sepsis approach — `,p,a?`, ${i} kg`:``]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`Definition — Phoenix Sepsis Criteria (JAMA 2024)`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-xs space-y-1`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Sepsis`}),` = suspected or confirmed infection + Phoenix Score ≥2 (organ dysfunction across respiratory, cardiovascular, coagulation, neurological).`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Septic shock`}),` = sepsis + cardiovascular dysfunction (vasoactive support, or ↑lactate ≥5, or ↓MAP for age).`]}),(0,l.jsx)(`div`,{className:`text-muted-foreground italic`,children:`Previous SIRS-based criteria (Goldstein 2005) are now superseded.`})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`Red flags`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-red-50 dark:bg-red-950/30 p-3 text-xs text-red-900 dark:text-red-100`,children:[`Abnormal behavior / mentation · Fever + ill-appearance · Tachycardia out of proportion to fever · Prolonged cap refill (>3 s) · Cold/mottled extremities · Weak pulses or wide pulse pressure ("warm shock") · Hypotension is a `,(0,l.jsx)(`strong`,{children:`LATE`}),` sign · Any immune compromise / indwelling line.`]}),(0,l.jsxs)(`h3`,{className:`text-sm font-semibold mt-2`,children:[`Empirical therapy — `,p]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-xs`,children:[n===`neonate`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`strong`,{children:`Workup (full sepsis eval):`}),` CBC+diff, CRP, blood culture, UA+urine culture (cath), `,(0,l.jsx)(`strong`,{children:`LP`}),` (CSF+HSV PCR), CXR if respiratory sx, procalcitonin. `,(0,l.jsx)(`strong`,{children:`Early-onset`}),` (<72 h): GBS, E. coli, Listeria. `,(0,l.jsx)(`strong`,{children:`Late-onset`}),` (>72 h): CoNS, S. aureus, gram-negs, Candida.`]}),n===`infant`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`strong`,{children:`Workup:`}),` Use validated rules — PECARN, Aronson, Rochester, Step-by-Step. CBC+ANC, procalcitonin/CRP, blood culture, UA+urine culture. Many warrant LP + admission + empiric abx. `,(0,l.jsx)(`strong`,{children:`Coverage:`}),` GBS, E. coli, Listeria (up to ~6 wk), S. pneumo, N. meningitidis, H. flu, Salmonella.`]}),n===`child`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`strong`,{children:`Recognition:`}),` Phoenix score or clinical concern + suspected infection. `,(0,l.jsx)(`strong`,{children:`Workup:`}),` CBC, CRP, procalcitonin, blood cx (+site-specific), lactate, blood gas, glucose, electrolytes, coags, LP if CNS concern. Source-directed imaging.`]})]}),a&&(0,l.jsxs)(g,{children:[n===`neonate`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(_,{name:`Ampicillin`,dose:(0,l.jsx)(h,{label:o(100,2e3).label}),route:`IV`,notes:`q8-12h. Covers GBS, Listeria, Enterococcus.`}),(0,l.jsx)(_,{name:`Gentamicin`,dose:(0,l.jsx)(h,{label:o(4,120).label}),route:`IV`,notes:`q24-48h. Monitor levels.`}),(0,l.jsx)(_,{name:`Cefotaxime (add)`,dose:(0,l.jsx)(h,{label:o(50,2e3).label}),route:`IV`,notes:`If meningitis or gram-neg concern.`}),(0,l.jsx)(_,{name:`Acyclovir`,dose:(0,l.jsx)(h,{label:o(20,1200).label}),route:`IV q8h`,notes:`HSV risk: maternal lesions, vesicles, seizures, CSF pleocytosis.`})]}),n===`infant`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(_,{name:`Ceftriaxone`,dose:(0,l.jsx)(h,{label:o(75,2e3).label}),route:`IV / IM`,notes:`q24h (100 mg/kg/day divided q12h for meningitis). <strong>Avoid <28 d</strong> if hyperbilirubinemia.`}),(0,l.jsx)(_,{name:`Ampicillin`,dose:(0,l.jsx)(h,{label:o(100,2e3).label}),route:`IV`,notes:`If <6 wk: add for Listeria coverage.`}),(0,l.jsx)(_,{name:`Vancomycin`,dose:(0,l.jsx)(h,{label:o(15,1e3).label}),route:`IV`,notes:`If severe / MRSA risk / meningitis.`}),(0,l.jsx)(_,{name:`Acyclovir`,dose:(0,l.jsx)(h,{label:o(20,1200).label}),route:`IV q8h`,notes:`<6 wk with suspicion of HSV.`})]}),n===`child`&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(_,{name:`Ceftriaxone`,dose:(0,l.jsx)(h,{label:o(50,2e3).label}),route:`IV`,notes:`q24h (100 mg/kg/day divided for meningitis).`}),(0,l.jsx)(_,{name:`Vancomycin`,dose:(0,l.jsx)(h,{label:o(15,1e3).label}),route:`IV`,notes:`q6h. If severe, indwelling line, or MRSA prevalence >10%.`}),(0,l.jsx)(_,{name:`Piperacillin-tazobactam`,dose:(0,l.jsx)(h,{label:o(100,4500).label}),route:`IV`,notes:`If intra-abdominal / neutropenic.`}),(0,l.jsx)(_,{name:`Clindamycin`,dose:(0,l.jsx)(h,{label:o(10,900).label}),route:`IV`,notes:`Adjunct for toxic shock syndrome (toxin suppression).`}),(0,l.jsx)(_,{name:`Acyclovir`,dose:(0,l.jsx)(h,{label:o(20,1200).label}),route:`IV q8h`,notes:`If HSV CNS concern.`})]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`First-hour bundle (SSC Peds 2020)`}),(0,l.jsxs)(`div`,{className:`space-y-2 text-sm`,children:[(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`0-5 min — Recognize`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`Screen, sepsis huddle/activation, ABCs, O₂ to SpO₂ >94%, warm.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-purple-500 bg-purple-50 dark:bg-purple-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`5-15 min — Access & labs`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`Two IVs or IO. Draw blood cx (ideally before abx), lactate, CBC, CMP, coags, blood gas, glucose. UA + culture. Source-specific cultures.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-amber-500 bg-amber-50 dark:bg-amber-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`15-30 min — Fluids`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[a?(0,l.jsxs)(l.Fragment,{children:[`NS or LR `,(0,l.jsxs)(`strong`,{children:[m,` mL`]}),` bolus (20 mL/kg) over 5-10 min.`]}):(0,l.jsx)(l.Fragment,{children:`NS/LR 10-20 mL/kg bolus over 5-10 min.`}),` Reassess HR, perfusion, lungs, liver. Repeat up to 40-60 mL/kg; stop if crackles/hepatomegaly.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-green-500 bg-green-50 dark:bg-green-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`30-60 min — Antibiotics + reassess`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:`Broad-spectrum empiric abx within 1 hour (≤1 h in septic shock). Recheck lactate, perfusion.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-destructive bg-red-50 dark:bg-red-950/30 p-3`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`>60 min — Fluid-refractory shock`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[`Start vasoactive (`,(0,l.jsx)(`strong`,{children:`epinephrine 0.05-0.3 mcg/kg/min`}),` cold / `,(0,l.jsx)(`strong`,{children:`norepinephrine 0.05-0.3 mcg/kg/min`}),` warm). Central/IO access. Stress-dose hydrocortisone `,a?(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`strong`,{children:[o(2,100).value,` mg`]}),` IV (2 mg/kg, max 100 mg)`]}):`2 mg/kg IV (max 100 mg)`,` if catecholamine-resistant. ICU.`]})]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`Resuscitation targets`}),(0,l.jsx)(`div`,{className:`rounded-md bg-muted/40 p-3 text-xs`,children:`Normal mentation · Cap refill ≤2 s · Warm extremities · Strong peripheral pulses · UOP ≥1 mL/kg/hr · MAP ≥5th %ile for age (>65 mmHg adolescent) · SpO₂ ≥94% · Lactate trending down.`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`Phoenix Sepsis Criteria (Schlapbach et al., JAMA 2024) · Surviving Sepsis Campaign Pediatric 2020 · AAP pediatric sepsis guidance.`})]})}var S=[{key:`head`,label:`Head`,vals:[18,13,11,9,7],ageSensitive:!0},{key:`neck`,label:`Neck`,vals:[2,2,2,2,2]},{key:`ant_trunk`,label:`Anterior trunk`,vals:[13,13,13,13,13]},{key:`post_trunk`,label:`Posterior trunk`,vals:[13,13,13,13,13]},{key:`r_buttock`,label:`Right buttock`,vals:[2.5,2.5,2.5,2.5,2.5]},{key:`l_buttock`,label:`Left buttock`,vals:[2.5,2.5,2.5,2.5,2.5]},{key:`genital`,label:`Genitalia`,vals:[1,1,1,1,1]},{key:`r_uparm`,label:`R upper arm`,vals:[4,4,4,4,4]},{key:`l_uparm`,label:`L upper arm`,vals:[4,4,4,4,4]},{key:`r_forearm`,label:`R forearm`,vals:[3,3,3,3,3]},{key:`l_forearm`,label:`L forearm`,vals:[3,3,3,3,3]},{key:`r_hand`,label:`R hand`,vals:[2.5,2.5,2.5,2.5,2.5]},{key:`l_hand`,label:`L hand`,vals:[2.5,2.5,2.5,2.5,2.5]},{key:`r_thigh`,label:`R thigh`,vals:[5.5,8,8.5,9,9.5],ageSensitive:!0},{key:`l_thigh`,label:`L thigh`,vals:[5.5,8,8.5,9,9.5],ageSensitive:!0},{key:`r_leg`,label:`R lower leg`,vals:[5,5.5,6,6.5,7],ageSensitive:!0},{key:`l_leg`,label:`L lower leg`,vals:[5,5.5,6,6.5,7],ageSensitive:!0},{key:`r_foot`,label:`R foot`,vals:[3.5,3.5,3.5,3.5,3.5]},{key:`l_foot`,label:`L foot`,vals:[3.5,3.5,3.5,3.5,3.5]}],C=[{id:`infant`,label:`Infant (<1 y)`},{id:`young`,label:`Young child (1-5 y)`},{id:`child`,label:`Child (5-10 y)`},{id:`adol`,label:`Adolescent (10-15 y)`},{id:`adult`,label:`Adult (>15 y)`}];function w(){let[e,t]=(0,c.useState)(``),[n,r]=(0,c.useState)(`young`),[i,a]=(0,c.useState)(``),[o,s]=(0,c.useState)({}),p=C.findIndex(e=>e.id===n),m=S.reduce((e,t)=>e+t.vals[p]*Math.min(100,Math.max(0,o[t.key]??0))/100,0),h=i.trim()?Number(i):Math.round(m*10)/10,g=Number.parseFloat(e),_=Number.isFinite(g)&&g>0,v=Number.isFinite(h)&&h>0,y=_&&v?Math.round(4*g*h):0,b=Math.round(y/2),x=Math.round(b/8),w=y-b,T=Math.round(w/16),E=_?Math.round(g<=10?g*4:g<=20?40+(g-10)*2:60+(g-20)):0;return(0,l.jsxs)(`section`,{className:u,"data-testid":`bedside-panel-burns`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Burns — Lund-Browder + Parkland`}),(0,l.jsxs)(`div`,{className:`grid gap-2 grid-cols-1 sm:grid-cols-3 max-w-xl`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Weight (kg)`}),(0,l.jsx)(`input`,{type:`number`,min:`0.3`,step:`0.1`,className:d,value:e,onChange:e=>t(e.target.value),"data-testid":`burn-weight`})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`Age band`}),(0,l.jsx)(`select`,{className:d,value:n,onChange:e=>r(e.target.value),"data-testid":`burn-age`,children:C.map(e=>(0,l.jsx)(`option`,{value:e.id,children:e.label},e.id))})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{className:f,children:`TBSA override (%)`}),(0,l.jsx)(`input`,{type:`number`,min:`0`,max:`100`,step:`1`,className:d,value:i,onChange:e=>a(e.target.value),placeholder:v?String(h):`auto`,"data-testid":`burn-tbsa`})]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold`,children:`Body parts — % of each region burned (2° or deeper)`}),(0,l.jsx)(`div`,{className:`grid grid-cols-1 sm:grid-cols-2 md:grid-cols-3 gap-2`,children:S.map(e=>{let t=e.vals[p];return(0,l.jsxs)(`div`,{className:`flex items-center gap-2 bg-muted/30 rounded p-2`,children:[(0,l.jsxs)(`label`,{className:`flex-1 text-xs`,children:[e.label,` `,(0,l.jsxs)(`span`,{className:`text-muted-foreground`,children:[`(`,t,`%`,e.ageSensitive?`*`:``,`)`]})]}),(0,l.jsx)(`input`,{type:`number`,min:`0`,max:`100`,step:`5`,className:`w-16 rounded border border-input bg-background px-2 py-1 text-xs text-right`,value:o[e.key]??0,onChange:t=>s({...o,[e.key]:Number(t.target.value)}),"data-testid":`burn-region-`+e.key}),(0,l.jsx)(`span`,{className:`text-xs text-muted-foreground`,children:`%`})]},e.key)})}),v&&(0,l.jsxs)(`div`,{className:`text-sm text-muted-foreground`,children:[`Computed TBSA: `,(0,l.jsxs)(`strong`,{children:[h,`%`]})]}),!_&&(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see Parkland + maintenance fluids.`}),!v&&_&&(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter % per region or override TBSA to compute fluids.`}),_&&v&&(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-destructive bg-red-50 dark:bg-red-950/30 p-3 text-sm font-semibold text-destructive`,"data-testid":`burn-result`,children:[`Burn fluid resuscitation — `,g,` kg, `,h,`% TBSA (2° or deeper)`]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-red-50 dark:bg-red-950/30 p-3 text-sm space-y-1`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Parkland formula:`}),` 4 mL × kg × %TBSA = `,(0,l.jsxs)(`strong`,{children:[y,` mL LR over 24 hours`]})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`First 8 h`}),` (from time of burn): `,b,` mL (~`,(0,l.jsxs)(`strong`,{children:[x,` mL/hr`]}),`)`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Next 16 h:`}),` `,w,` mL (~`,(0,l.jsxs)(`strong`,{children:[T,` mL/hr`]}),`)`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-sm`,children:[(0,l.jsx)(`strong`,{children:`Plus maintenance (4-2-1):`}),` `,E,` mL/hr (D5 ½NS ± 20 mEq KCl/L once UOP established). Consider dextrose in children <30 kg.`]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-sm`,children:[(0,l.jsx)(`strong`,{children:`Titrate to UOP:`}),` target 1-2 mL/kg/hr (infants / children), 0.5-1 mL/kg/hr (adolescents). `,(0,l.jsx)(`strong`,{children:`Clinical response trumps formula.`})]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold`,children:`Other pearls`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-xs space-y-1`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Rule of palm:`}),` Patient's palm + fingers ≈ 1% TBSA — good for scattered burns.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`First-degree burns DO NOT count`}),` toward TBSA or Parkland.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Analgesia:`}),` Morphine 0.05-0.1 mg/kg IV q2h, or fentanyl 1-2 mcg/kg IV q30-60 min.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Tetanus`}),` prophylaxis if indicated. Tdap/Td ± TIG.`]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold`,children:`Burn center referral (ABA)`}),(0,l.jsx)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:`Partial-thickness >10% TBSA · any full-thickness · face/hands/feet/genital/perineum/major joints · electrical/chemical/inhalation · associated trauma · significant comorbidities · pediatric burns in non-pediatric center.`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`ABA Advanced Burn Life Support 2018 · Parkland formula: Baxter 1968 · Lund-Browder 1944.`})]})}var T=`rounded-lg border border-border bg-card p-5 space-y-3`,E=`w-full rounded-md border border-input bg-background px-3 py-2 text-sm outline-none focus:ring-2 focus:ring-ring`,D=`block text-xs font-medium text-muted-foreground`,O=`text-left px-2 py-1.5 border-b border-border font-semibold uppercase tracking-wide text-[10px] text-muted-foreground`,k=`px-2 py-1.5 border-b border-border align-top text-sm`;function A({id:e,value:t,onChange:n,testid:r}){return(0,l.jsxs)(`div`,{className:`max-w-xs`,children:[(0,l.jsx)(`label`,{htmlFor:e,className:D,children:`Weight (kg)`}),(0,l.jsx)(`input`,{id:e,type:`number`,min:`0.3`,step:`0.1`,className:E,value:t,onChange:e=>n(e.target.value),"data-testid":r})]})}function j({label:e}){let t=e.indexOf(`(`);if(t<0)return(0,l.jsx)(`span`,{className:`font-semibold`,children:e});let n=e.slice(0,t).trim(),r=e.slice(t);return(0,l.jsxs)(`span`,{children:[(0,l.jsx)(`span`,{className:`font-semibold`,children:n}),` `,(0,l.jsx)(`span`,{className:`text-xs text-muted-foreground`,children:r})]})}var M={epi:{perKg:.01,max:.5,unit:`mg`},fluids:{perKg:20,max:null,unit:`mL`},dph:{perKg:1.25,max:50,unit:`mg`},ranitidine:{perKg:1,max:50,unit:`mg`},dex:{perKg:.6,max:16,unit:`mg`},mpn:{perKg:2,max:125,unit:`mg`},glucagon:{perKg:.02,max:1,unit:`mg`}};function N(){let[e,t]=(0,c.useState)(``),n=Number.parseFloat(e);if(!Number.isFinite(n)||n<=0)return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-anaphylaxis`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Anaphylaxis`}),(0,l.jsx)(`p`,{className:`text-sm text-muted-foreground`,children:`Emergency management. Epinephrine IM is the immediate and only proven lifesaving step.`}),(0,l.jsx)(A,{id:`anaph-wt`,value:e,onChange:t,testid:`anaph-weight`}),(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see doses.`})]});let r=s(n,M.epi.perKg,M.epi.max,M.epi.unit),i=Math.round(r.value*10)/10,a=n<10?`Draw up manually`:n<=25?`EpiPen Jr / Auvi-Q 0.15 mg`:`EpiPen / Auvi-Q 0.3 mg`,o=s(n,M.fluids.perKg,M.fluids.max,M.fluids.unit),u=s(n,M.dph.perKg,M.dph.max),d=s(n,M.ranitidine.perKg,M.ranitidine.max),f=s(n,M.dex.perKg,M.dex.max),p=s(n,M.mpn.perKg,M.mpn.max),m=s(n,M.glucagon.perKg,M.glucagon.max),h=[[`STEP 2`,`Position`,`Supine + legs elevated`,`—`,`If dyspneic: sitting position. If vomiting: recovery position`],[`STEP 3`,`O₂`,`High flow 10-15 L/min`,`Face mask`,`100% O₂. Prepare for airway management`],[`STEP 4`,`IV fluids`,`NS ${o.label} bolus`,`IV/IO`,`Repeat up to 60 mL/kg for hypotension`],[`STEP 5`,`Diphenhydramine`,u.label,`IV/IM/PO`,`H1 blocker. NOT first-line — adjunct only`],[``,`Ranitidine`,d.label,`IV over 5 min`,`H2 blocker. Optional adjunct`],[`STEP 6`,`Dexamethasone`,f.label,`IV/IM/PO`,`Prevents biphasic reaction (4-6 hrs later)`],[``,`Methylprednisolone`,p.label,`IV`,`Alternative steroid`],[`REFRACTORY`,`Epinephrine gtt`,`0.1-1 mcg/kg/min`,`IV infusion`,`For persistent hypotension despite fluids + IM epi`],[``,`Glucagon`,m.label,`IV/IM`,`For patients on beta-blockers not responding to epi`]];return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-anaphylaxis`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Anaphylaxis`}),(0,l.jsx)(A,{id:`anaph-wt`,value:e,onChange:t,testid:`anaph-weight`}),(0,l.jsxs)(`div`,{className:`rounded-lg border-2 border-destructive bg-red-50 dark:bg-red-950/30 p-4 space-y-1`,children:[(0,l.jsx)(`div`,{className:`text-base font-bold text-destructive`,children:`STEP 1: Epinephrine IM — GIVE IMMEDIATELY`}),(0,l.jsxs)(`div`,{className:`text-sm font-semibold`,children:[`Epinephrine 1:1000 (1 mg/mL): `,(0,l.jsxs)(`span`,{className:`text-destructive`,children:[r.value,` mg (`,i,` mL)`]}),` IM to lateral thigh`]}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground`,children:[M.epi.perKg,` mg/kg (max `,M.epi.max,` mg) · Auto-injector: `,a]}),(0,l.jsx)(`div`,{className:`text-xs text-destructive`,children:`May repeat every 5-15 minutes if symptoms persist. No contraindications in anaphylaxis.`})]}),(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,"data-testid":`anaph-table`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Step`}),(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:h.map((e,t)=>(0,l.jsxs)(`tr`,{className:e[0]===`REFRACTORY`||t>0&&h[t-1][0]===`REFRACTORY`&&e[0]===``?`bg-amber-50 dark:bg-amber-950/30`:``,children:[(0,l.jsx)(`td`,{className:k+` font-semibold text-primary text-xs`,children:e[0]}),(0,l.jsx)(`td`,{className:k+` font-semibold`,children:e[1]}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:e[2]})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:e[3]}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:e[4]})]},t))})]})}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Observe minimum 4-6 hours`}),` after last dose of epinephrine (biphasic reactions occur in 5-20% of cases). Discharge with EpiPen prescription and anaphylaxis action plan. Refer to allergist.`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`ASCIA Anaphylaxis Guidelines 2021 · WAO Anaphylaxis Guidance 2020 · AAP/ACAAI Practice Parameters.`})]})}function P(){let[e,t]=(0,c.useState)(``),[n,r]=(0,c.useState)(`general`),i=Number.parseFloat(e),a=Number.isFinite(i)&&i>0,o=(e,t,n=`mg`)=>a?s(i,e,t,n):null,u=[{id:`general`,label:`PALS General`},{id:`asystole`,label:`Asystole / PEA`},{id:`brady`,label:`Bradycardia`},{id:`svt`,label:`SVT`},{id:`vfib`,label:`VF / Pulseless VT`},{id:`vt`,label:`Stable VT`}];function d({name:e,dose:t,route:n,notes:r}){return(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:e}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:t})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:n}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:r})]})}function f({children:e}){return(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:e})]})})}function p(){if(!a)return null;let e=o(.01,1,`mg`),t=o(.1,10,`mL`),n=o(.1,2.5,`mg`),r=o(5,300,`mg`),i=o(1,100,`mg`),s=o(.02,.5,`mg`),c=o(.1,6,`mg`),u=o(.2,12,`mg`),p=o(1,50,`mEq`),m=o(20,1e3,`mg`),h=o(.2,10,`mL`),g=o(60,3e3,`mg`),_=o(.6,30,`mL`),v=o(50,2e3,`mg`),y=o(2,null,`mL`);return(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{name:`Epinephrine 1:10,000`,dose:`${e.label} (${t.label})`,route:`IV / IO`,notes:`0.01 mg/kg = 0.1 mL/kg of 1:10,000. Max single dose 1 mg. Repeat q3-5 min.`}),(0,l.jsx)(d,{name:`Epinephrine ET`,dose:n.label,route:`ETT`,notes:`0.1 mg/kg (1 mL/kg of 1:10,000) if no IV/IO`}),(0,l.jsx)(d,{name:`Amiodarone`,dose:r.label,route:`IV / IO bolus`,notes:`5 mg/kg for arrest. Max 300 mg. Repeat up to 2 times (max 15 mg/kg/day).`}),(0,l.jsx)(d,{name:`Lidocaine`,dose:i.label,route:`IV / IO bolus`,notes:`1 mg/kg. Alternative to amiodarone for VF/VT.`}),(0,l.jsx)(d,{name:`Atropine`,dose:`${s.label} (min 0.1 mg)`,route:`IV / IO`,notes:`0.02 mg/kg. Bradycardia from ↑vagal tone or AV block.`}),(0,l.jsx)(d,{name:`Adenosine (1st)`,dose:c.label,route:`IV push + flush`,notes:`0.1 mg/kg (max 6 mg). For SVT. Rapid push, double flush.`}),(0,l.jsx)(d,{name:`Adenosine (2nd)`,dose:u.label,route:`IV push + flush`,notes:`0.2 mg/kg (max 12 mg). Second dose if first unsuccessful.`}),(0,l.jsx)(d,{name:`Sodium bicarb 8.4%`,dose:p.label,route:`IV / IO`,notes:`1 mEq/kg. ONLY if severe metabolic acidosis, hyperK, or TCA OD. Not routine.`}),(0,l.jsx)(d,{name:`Calcium chloride 10%`,dose:`${m.label} (${h.label})`,route:`IV / IO (central preferred)`,notes:`For hyperK, hypoCa, Mg OD, CCB OD. 20 mg/kg = 0.2 mL/kg.`}),(0,l.jsx)(d,{name:`Calcium gluconate 10%`,dose:`${g.label} (${_.label})`,route:`IV / IO (peripheral OK)`,notes:`60 mg/kg = 0.6 mL/kg. Preferred peripherally.`}),(0,l.jsx)(d,{name:`Magnesium sulfate`,dose:v.label,route:`IV over 10-20 min`,notes:`25-50 mg/kg. Torsades, severe asthma. Max 2 g.`}),(0,l.jsx)(d,{name:`Dextrose 10%`,dose:`${y.label} (0.2 g/kg)`,route:`IV push`,notes:`For documented hypoglycemia`}),(0,l.jsx)(d,{name:`Defibrillation`,dose:`2 J/kg → 4 J/kg → 10 J/kg (max 10 J/kg or adult dose)`,route:`Pad`,notes:`For VF/pulseless VT. Resume CPR immediately after shock.`}),(0,l.jsx)(d,{name:`Cardioversion (sync)`,dose:`0.5-1 J/kg → 2 J/kg`,route:`Pad`,notes:`For unstable SVT/VT. Sedate if possible.`})]})}function m(){if(!a)return null;let e=o(.01,1,`mg`),t=o(.1,2.5,`mg`);return(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{name:`CPR`,dose:`100-120/min, depth 1/3 AP`,route:`—`,notes:`15:2 (2 rescuer) or 30:2 (single). Rotate every 2 min.`}),(0,l.jsx)(d,{name:`Epinephrine`,dose:e.label,route:`IV / IO`,notes:`0.01 mg/kg 1:10,000 = 0.1 mL/kg. Q3-5 min. Start early.`}),(0,l.jsx)(d,{name:`Epinephrine ETT`,dose:t.label,route:`ETT`,notes:`0.1 mg/kg if no IV access`})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`Reversible causes (H's & T's)`}),(0,l.jsxs)(`div`,{className:`grid grid-cols-1 md:grid-cols-2 gap-2 text-xs`,children:[(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-2`,children:[(0,l.jsx)(`strong`,{children:`H's`}),` — Hypoxia, Hypovolemia, H+ (acidosis), Hypo/hyperK, Hypoglycemia, Hypothermia`]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-2`,children:[(0,l.jsx)(`strong`,{children:`T's`}),` — Tension PTX, Tamponade, Toxins, Thrombosis (MI/PE), Trauma`]})]})]})}function h(){if(!a)return null;let e=o(.01,1,`mg`),t=o(.02,.5,`mg`);return(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-amber-500 bg-amber-50 dark:bg-amber-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-amber-800 dark:text-amber-200`,children:`Bradycardia with poor perfusion (HR < 60)`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Start CPR if HR < 60 with poor perfusion despite oxygenation and ventilation.`})]}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{name:`Epinephrine`,dose:e.label,route:`IV / IO`,notes:`First-line. Q3-5 min.`}),(0,l.jsx)(d,{name:`Atropine`,dose:`${t.label} (min 0.1 mg)`,route:`IV / IO`,notes:`If ↑ vagal tone or AV block. Max 1 mg child / 0.5 mg infant.`}),(0,l.jsx)(d,{name:`Transcutaneous pacing`,dose:`—`,route:`Pad`,notes:`For refractory bradycardia not responsive to drugs.`}),(0,l.jsx)(d,{name:`Consider`,dose:`—`,route:`—`,notes:`Hypoxia, tension pneumothorax, ↑ICP, toxic ingestion (organo, CCB, BB), heart block`})]})]})}function g(){if(!a)return null;let e=o(.1,6,`mg`),t=o(.2,12,`mg`);return(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-blue-800 dark:text-blue-200`,children:`SVT — narrow complex, rate usually >220 infant / >180 child`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Differentiate from sinus tach: abrupt onset/offset, no P waves or abnormal P axis, HR minimally variable.`})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold`,children:`If STABLE`}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{name:`Vagal maneuvers`,dose:`Ice to face, blow into syringe, Valsalva`,route:`—`,notes:`Try first in stable patient`}),(0,l.jsx)(d,{name:`Adenosine (1st)`,dose:e.label,route:`IV push (proximal) + flush`,notes:`Rapid push, 3-way stopcock with NS flush`}),(0,l.jsx)(d,{name:`Adenosine (2nd)`,dose:t.label,route:`IV push + flush`,notes:`If first dose unsuccessful`}),(0,l.jsx)(d,{name:`Procainamide`,dose:`15 mg/kg over 30-60 min`,route:`IV`,notes:`Expert consult. Avoid with amiodarone.`}),(0,l.jsx)(d,{name:`Amiodarone`,dose:`5 mg/kg over 20-60 min`,route:`IV`,notes:`Expert consult.`})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold`,children:`If UNSTABLE`}),(0,l.jsx)(f,{children:(0,l.jsx)(d,{name:`Synchronized cardioversion`,dose:`0.5-1 J/kg → 2 J/kg`,route:`Pad`,notes:`Sedate if possible. Pre-treat with adenosine if IV available.`})})]})}function _(){if(!a)return null;let e=o(.01,1,`mg`),t=o(5,300,`mg`),n=o(1,100,`mg`),r=o(50,2e3,`mg`);return(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-destructive bg-red-50 dark:bg-red-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-destructive`,children:`VF / Pulseless VT`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`High-quality CPR + defibrillation are key. Minimize interruptions.`})]}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{name:`Defibrillation (1st)`,dose:`2 J/kg`,route:`Pad`,notes:`Resume CPR immediately after shock.`}),(0,l.jsx)(d,{name:`Defibrillation (2nd)`,dose:`4 J/kg`,route:`Pad`,notes:`After 2 min CPR.`}),(0,l.jsx)(d,{name:`Defibrillation (3rd+)`,dose:`≥4 J/kg (max 10 J/kg or adult dose)`,route:`Pad`,notes:``}),(0,l.jsx)(d,{name:`Epinephrine`,dose:e.label,route:`IV / IO`,notes:`After 2nd shock. Q3-5 min.`}),(0,l.jsx)(d,{name:`Amiodarone`,dose:t.label,route:`IV / IO bolus`,notes:`Refractory VF/VT. Max 15 mg/kg/day.`}),(0,l.jsx)(d,{name:`Lidocaine`,dose:n.label,route:`IV / IO`,notes:`Alternative to amiodarone. Then 20-50 mcg/kg/min gtt.`}),(0,l.jsx)(d,{name:`Mg sulfate`,dose:r.label,route:`IV over 1-2 min`,notes:`For torsades or hypoMg.`})]})]})}function v(){if(!a)return null;let e=o(5,300,`mg`);return(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-amber-500 bg-amber-50 dark:bg-amber-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-amber-800 dark:text-amber-200`,children:`Stable monomorphic VT`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Expert consult. Avoid combining QT-prolonging agents.`})]}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{name:`Amiodarone`,dose:`5 mg/kg over 20-60 min = ${e.value} mg over 20-60 min`,route:`IV`,notes:``}),(0,l.jsx)(d,{name:`Procainamide`,dose:`15 mg/kg over 30-60 min`,route:`IV`,notes:`Do not combine with amiodarone`}),(0,l.jsx)(d,{name:`Sync cardioversion`,dose:`0.5-1 → 2 J/kg`,route:`Pad`,notes:`If becomes unstable. Sedate.`})]})]})}return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-cardiac`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Cardiac Arrest / PALS`}),(0,l.jsx)(A,{id:`cardiac-wt`,value:e,onChange:t,testid:`cardiac-weight`}),(0,l.jsx)(`div`,{className:`flex flex-wrap gap-2`,children:u.map(e=>(0,l.jsx)(`button`,{type:`button`,onClick:()=>r(e.id),className:`px-3 py-1.5 rounded-full text-xs font-medium border `+(n===e.id?`bg-primary text-primary-foreground border-primary`:`bg-muted hover:bg-muted/80 border-border`),"data-testid":`cardiac-view-`+e.id,children:e.label},e.id))}),a?(0,l.jsxs)(`div`,{className:`space-y-3`,children:[(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-destructive bg-red-50 dark:bg-red-950/30 p-3 text-sm font-semibold text-destructive`,children:[u.find(e=>e.id===n)?.label,` — `,i,` kg`]}),n===`general`&&(0,l.jsx)(p,{}),n===`asystole`&&(0,l.jsx)(m,{}),n===`brady`&&(0,l.jsx)(h,{}),n===`svt`&&(0,l.jsx)(g,{}),n===`vfib`&&(0,l.jsx)(_,{}),n===`vt`&&(0,l.jsx)(v,{}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Concentrations:`}),` Epi 1:10,000 (0.1 mg/mL) for IV arrest. 1:1000 (1 mg/mL) for IM anaphylaxis. Atropine <0.1 mg can cause paradoxical bradycardia.`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`AHA PALS Guidelines 2020 · Always verify against institutional protocols.`})]}):(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see doses.`})]})}var F={lorazepam:{perKg:.1,max:4,unit:`mg`,route:`IV / IO`,note:`Slow push over 1-2 min.`,suffix:` (IV preferred)`},midazolam:{perKg:.2,max:10,unit:`mg`,route:`IM / IN / buccal`,note:`Use 5 mg/mL concentrate for IN; split between nares.`},diazepam:{perKg:.5,max:20,unit:`mg`,route:`PR`,note:`Only if no IV/IM/IN access.`},levetiracetam:{perKg:60,max:4500,unit:`mg`,route:`IV over 5-15 min`,note:`Best tolerability. No ECG monitoring needed.`,suffix:` (preferred)`},fosphenytoin:{perKg:20,max:1500,unit:`mg PE`,route:`IV over 10 min`,note:`Max rate 3 mg PE/kg/min. Monitor ECG, BP. Avoid if cardiac dysrhythmia.`},valproate:{perKg:40,max:3e3,unit:`mg`,route:`IV over 10 min`,note:`Avoid <2 yr, hepatic / mitochondrial disease, pregnancy.`},phenobarb:{perKg:20,max:1e3,unit:`mg`,route:`IV over 20 min`,note:`Last-choice 2nd line. High risk of resp depression + hypotension.`},midazGttBolus:{perKg:.2,max:10,unit:`mg`},midazGttLow:{perKg:.05,max:2,unit:`mg/hr`},midazGttHigh:{perKg:.5,max:18,unit:`mg/hr`},pentobarbBolus:{perKg:5,max:200,unit:`mg`},pentobarbGttLow:{perKg:1,max:null,unit:`mg/hr`},pentobarbGttHigh:{perKg:5,max:null,unit:`mg/hr`},propofolBolus:{perKg:2,max:100,unit:`mg`},propofolGttLow:{perKg:2,max:null,unit:`mg/hr`},propofolGttHigh:{perKg:5,max:null,unit:`mg/hr`},ketamineBolus:{perKg:2,max:100,unit:`mg`},ketamineGttLow:{perKg:1,max:null,unit:`mg/hr`},ketamineGttHigh:{perKg:5,max:null,unit:`mg/hr`}};function I(){let[e,t]=(0,c.useState)(``),n=Number.parseFloat(e),r=Number.isFinite(n)&&n>0,i=(e,t,i=`mg`)=>r?s(n,e,t,i):null,a=r?Math.round(n*2*10)/10:0,o=r?Math.round(n*5*10)/10:0;function u({time:e,color:t,title:n,children:r,last:i=!1}){return(0,l.jsxs)(`div`,{className:`flex gap-3`,children:[(0,l.jsxs)(`div`,{className:`flex flex-col items-center flex-shrink-0`,children:[(0,l.jsx)(`div`,{className:`w-16 py-1.5 rounded-full text-white text-xs font-bold text-center ${t}`,children:e}),!i&&(0,l.jsx)(`div`,{className:`w-0.5 flex-1 bg-border mt-1`})]}),(0,l.jsxs)(`div`,{className:`flex-1 rounded-r-md border-l-4 p-3 bg-muted/30`,style:{borderLeftColor:`currentColor`},children:[(0,l.jsx)(`div`,{className:`text-xs font-bold uppercase tracking-wide mb-2`,children:n}),(0,l.jsx)(`div`,{className:`text-sm space-y-2`,children:r})]})]})}function d({name:e,f:t,route:n,notes:r,suffix:i}){return(0,l.jsxs)(`tr`,{children:[(0,l.jsxs)(`td`,{className:k+` font-semibold`,children:[e,i&&(0,l.jsx)(`span`,{className:`text-xs text-green-700 ml-1`,children:i})]}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:t.label})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:n}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,dangerouslySetInnerHTML:{__html:r}})]})}return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-seizure`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Seizures — Status Epilepticus Pathway`}),(0,l.jsx)(A,{id:`seizure-wt`,value:e,onChange:t,testid:`seizure-weight`}),r?(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-destructive bg-red-50 dark:bg-red-950/30 p-3`,children:[(0,l.jsxs)(`div`,{className:`font-bold text-destructive text-sm`,children:[`Status Epilepticus Pathway — `,n,` kg`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Time = 0 at seizure onset. Do not pause between steps for benzo to take effect — act on the clock.`})]}),(0,l.jsxs)(`div`,{className:`space-y-0`,children:[(0,l.jsxs)(u,{time:`0 min`,color:`bg-blue-500 text-white`,title:`Stabilize`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`ABCs`}),` — position, 100% O₂ via NC / NRB, suction. `,(0,l.jsx)(`strong`,{children:`IV or IO`}),` × 2. Continuous SpO₂, ECG, BP.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`POC glucose`}),` — if <60 mg/dL: `,(0,l.jsxs)(`strong`,{children:[`D10W `,a,`-`,o,` mL IV`]}),` (2-5 mL/kg).`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Labs`}),`: CBC, CMP, Mg, Ca, Phos, VBG, lactate, AED levels, toxicology if unclear etiology.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Consider pyridoxine`}),` 100 mg IV in infants <18 mo or INH ingestion. Temperature: treat hyperthermia aggressively.`]})]}),(0,l.jsx)(u,{time:`5 min`,color:`bg-purple-500 text-white`,title:`1st benzodiazepine (give once, pick by access)`,children:(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsxs)(`tbody`,{children:[(0,l.jsx)(d,{name:`Lorazepam`,f:i(F.lorazepam.perKg,F.lorazepam.max),route:`IV / IO`,notes:`Slow push over 1-2 min.`,suffix:` (IV preferred)`}),(0,l.jsx)(d,{name:`Midazolam`,f:i(F.midazolam.perKg,F.midazolam.max),route:`IM / IN / buccal`,notes:`Use 5 mg/mL concentrate for IN; split between nares.`}),(0,l.jsx)(d,{name:`Diazepam`,f:i(F.diazepam.perKg,F.diazepam.max),route:`PR`,notes:`Only if no IV/IM/IN access.`})]})]})})}),(0,l.jsxs)(u,{time:`10 min`,color:`bg-violet-500 text-white`,title:`2nd benzodiazepine — if still seizing`,children:[`Repeat same agent + dose `,(0,l.jsx)(`strong`,{children:`once`}),`. Prepare 2nd-line now (don't wait to see if benzo works). If apnea/airway compromise: BVM, consider advanced airway.`]}),(0,l.jsx)(u,{time:`20 min`,color:`bg-amber-500 text-white`,title:`2nd-line anti-epileptic — pick one (ESETT: equivalent efficacy)`,children:(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsxs)(`tbody`,{children:[(0,l.jsx)(d,{name:`Levetiracetam`,f:i(F.levetiracetam.perKg,F.levetiracetam.max),route:`IV over 5-15 min`,notes:`Best tolerability. No ECG monitoring needed.`,suffix:` (preferred)`}),(0,l.jsx)(d,{name:`Fosphenytoin`,f:i(F.fosphenytoin.perKg,F.fosphenytoin.max,`mg PE`),route:`IV over 10 min`,notes:`Max rate 3 mg PE/kg/min. Monitor ECG, BP. Avoid if cardiac dysrhythmia.`}),(0,l.jsx)(d,{name:`Valproic acid`,f:i(F.valproate.perKg,F.valproate.max),route:`IV over 10 min`,notes:`<strong>Avoid <2 yr, hepatic / mitochondrial disease, pregnancy.</strong>`}),(0,l.jsx)(d,{name:`Phenobarbital`,f:i(F.phenobarb.perKg,F.phenobarb.max),route:`IV over 20 min`,notes:`Last-choice 2nd line. High risk of resp depression + hypotension.`})]})]})})}),(0,l.jsxs)(u,{time:`30 min`,color:`bg-red-500 text-white`,title:`Still seizing? Consider 2nd agent from 2nd-line OR proceed to refractory`,children:[`If the first 2nd-line drug failed, give a different 2nd-line agent `,(0,l.jsx)(`strong`,{children:`OR`}),` move directly to refractory therapy. Activate ICU, prepare for intubation. Confirm etiology not reversible (electrolytes, glucose, fever, toxin).`]}),(0,l.jsxs)(u,{time:`40 min`,color:`bg-destructive text-white`,title:`Refractory status — intubate + continuous infusion + continuous EEG`,last:!0,children:[(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsxs)(`tbody`,{children:[(0,l.jsxs)(`tr`,{children:[(0,l.jsxs)(`td`,{className:k+` font-semibold`,children:[`Midazolam `,(0,l.jsx)(`span`,{className:`text-xs text-green-700`,children:`(1st-line infusion)`})]}),(0,l.jsxs)(`td`,{className:k+` text-sm`,children:[`Bolus `,i(F.midazGttBolus.perKg,F.midazGttBolus.max).value,` mg → gtt `,i(F.midazGttLow.perKg,F.midazGttLow.max,`mg/hr`).value,`–`,i(F.midazGttHigh.perKg,F.midazGttHigh.max,`mg/hr`).value,` mg/hr `,(0,l.jsx)(`span`,{className:`text-xs text-muted-foreground`,children:`(bolus 0.2 mg/kg, gtt 0.05-0.5 mg/kg/hr)`})]}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`IV`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`Titrate to seizure control / burst suppression.`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Pentobarbital`}),(0,l.jsxs)(`td`,{className:k+` text-sm`,children:[`Bolus `,i(F.pentobarbBolus.perKg,F.pentobarbBolus.max).value,` mg → gtt `,i(F.pentobarbGttLow.perKg,null,`mg/hr`).value,`–`,i(F.pentobarbGttHigh.perKg,null,`mg/hr`).value,` mg/hr `,(0,l.jsx)(`span`,{className:`text-xs text-muted-foreground`,children:`(bolus 5 mg/kg, gtt 1-5 mg/kg/hr)`})]}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`IV`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`Causes hypotension — often need pressors.`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Propofol`}),(0,l.jsxs)(`td`,{className:k+` text-sm`,children:[`Bolus `,i(F.propofolBolus.perKg,F.propofolBolus.max).value,` mg → gtt `,i(F.propofolGttLow.perKg,null,`mg/hr`).value,`–`,i(F.propofolGttHigh.perKg,null,`mg/hr`).value,` mg/hr `,(0,l.jsx)(`span`,{className:`text-xs text-muted-foreground`,children:`(bolus 2 mg/kg, gtt 2-5 mg/kg/hr)`})]}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`IV`}),(0,l.jsxs)(`td`,{className:k+` text-xs text-muted-foreground`,children:[(0,l.jsx)(`strong`,{children:`PRIS risk in children`}),` — limit to <4 mg/kg/hr and duration <48 h.`]})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Ketamine`}),(0,l.jsxs)(`td`,{className:k+` text-sm`,children:[`Bolus `,i(F.ketamineBolus.perKg,F.ketamineBolus.max).value,` mg → gtt `,i(F.ketamineGttLow.perKg,null,`mg/hr`).value,`–`,i(F.ketamineGttHigh.perKg,null,`mg/hr`).value,` mg/hr `,(0,l.jsx)(`span`,{className:`text-xs text-muted-foreground`,children:`(bolus 2 mg/kg, gtt 1-5 mg/kg/hr)`})]}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`IV`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`NMDA antagonist — rescue. Good BP profile; useful if refractory to GABAergics.`})]})]})]})}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground mt-2`,children:[(0,l.jsx)(`strong`,{children:`Continuous EEG within 1 h`}),` — target electrographic seizure suppression × 24-48 h, then wean. Reassess etiology: CNS imaging, LP, expanded workup.`]})]})]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100 space-y-1`,children:[(0,l.jsx)(`div`,{className:`font-semibold`,children:`Key points`}),(0,l.jsxs)(`div`,{children:[`• Do `,(0,l.jsx)(`strong`,{children:`NOT`}),` wait for benzo response before starting the 2nd-line — parallel preparation.`]}),(0,l.jsxs)(`div`,{children:[`• Maximum `,(0,l.jsx)(`strong`,{children:`2 benzo doses`}),` total (1 pre-hospital + 1 in ED, or 2 in ED).`]}),(0,l.jsx)(`div`,{children:`• Respiratory depression is common — have BVM, airway equipment, naloxone, flumazenil accessible (but avoid flumazenil here).`}),(0,l.jsx)(`div`,{children:`• ESETT trial: levetiracetam = fosphenytoin = valproate for efficacy. Pick by tolerability / contraindications.`}),(0,l.jsx)(`div`,{children:`• Always reassess: ongoing seizure? Non-convulsive status? Pseudo-seizure? → continuous EEG if any doubt.`})]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`Based on AES Guidelines 2016 and ESETT (Kapur et al., NEJM 2019). Verify all doses against institutional protocols.`})]}):(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see doses.`})]})}function L(){let[e,t]=(0,c.useState)(``),[n,r]=(0,c.useState)(``),i=Number.parseFloat(e),a=Number.parseFloat(n),o=Number.isFinite(i)&&i>0,u=(e,t,n=`mg`)=>o?s(i,e,t,n):null,d=Number.isFinite(a)&&a>=0,f=d?Math.round((a/4+4)*2)/2:null,p=d?Math.round((a/4+3.5)*2)/2:null,m=f?Math.round(f*3*10)/10:null,h=d?a<1?`Miller 0-1`:a<2?`Miller 1 / Mac 1`:a<8?`Miller 2 / Mac 2`:`Miller/Mac 3`:`—`,g=o?i<5?`1`:i<10?`1.5`:i<20?`2`:i<30?`2.5`:i<50?`3`:i<70?`4`:`5`:`—`,_=o&&i<10?2:1.5,v=u(6,null,`mL`),y=u(8,null,`mL`);function b({title:e,rows:t}){return(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:e}),(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:t.map((e,t)=>(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:e[0]}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:e[1]})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:e[2]}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:e[3]})]},t))})]})})]})}return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-airway`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Airway / RSI`}),(0,l.jsxs)(`div`,{className:`grid grid-cols-1 sm:grid-cols-2 gap-3 max-w-md`,children:[(0,l.jsx)(A,{id:`airway-wt`,value:e,onChange:t,testid:`airway-weight`}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{htmlFor:`airway-age`,className:D,children:`Age (years)`}),(0,l.jsx)(`input`,{id:`airway-age`,type:`number`,min:`0`,step:`0.5`,className:E,value:n,onChange:e=>r(e.target.value),"data-testid":`airway-age`})]})]}),o?(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold text-blue-900 dark:text-blue-100`,children:[`RSI doses & equipment — `,i,` kg`,d?`, ~${a} yr`:``]}),(0,l.jsx)(b,{title:`Pre-medication (optional)`,rows:[[`Atropine`,`${u(.02,1,`mg`).label} (min 0.1 mg)`,`IV`,`Consider <1 yr or if using succinylcholine, or bradycardia risk`],[`Lidocaine 2%`,u(1.5,100,`mg`).label,`IV over 1 min`,`For ↑ICP, asthma; give 2-3 min pre-induction`],[`Fentanyl`,`${u(2,150,`mcg`).label} (2-3 mcg/kg)`,`IV over 1 min`,`Blunts sympathetic response; avoid if hypotensive`]]}),(0,l.jsx)(b,{title:`Induction`,rows:[[`Ketamine`,`${u(1.5,150,`mg`).label} (1-2 mg/kg)`,`IV`,`Preserves BP. First-line for shock, asthma, sepsis`],[`Etomidate`,u(.3,30,`mg`).label,`IV`,`Hemodynamically neutral. Avoid in septic shock (adrenal suppression)`],[`Propofol`,`${u(2,200,`mg`).label} (1-2 mg/kg)`,`IV`,`Causes hypotension. Avoid in shock`],[`Midazolam`,u(.2,10,`mg`).label,`IV`,`Less optimal induction — slower onset`]]}),(0,l.jsx)(b,{title:`Paralytics`,rows:[[`Rocuronium`,`${u(1.2,100,`mg`).label} (1-1.2 mg/kg)`,`IV`,`30-60 sec onset; 30-45 min duration. First-line non-depolarizing.`],[`Succinylcholine`,u(_,150,`mg`).label,`IV`,`<10kg: 2 mg/kg; ≥10kg: 1.5 mg/kg. Avoid in burns/crush/hyperK/MH/NM dz. IM option: 4 mg/kg.`],[`Vecuronium`,u(.1,10,`mg`).label,`IV`,`2-3 min onset; longer duration than roc`]]}),(0,l.jsx)(b,{title:`Maintenance sedation / analgesia`,rows:[[`Midazolam gtt`,`${u(.05,2,`mg`).label}–${u(.2,10,`mg`).label}/hr`,`IV infusion`,`0.05-0.2 mg/kg/hr`],[`Fentanyl gtt`,`${u(1,100,`mcg`).label}–${u(4,200,`mcg`).label}/hr`,`IV infusion`,`1-4 mcg/kg/hr`],[`Ketamine gtt`,`${u(.5,30,`mg`).label}–${u(2,100,`mg`).label}/hr`,`IV infusion`,`0.5-2 mg/kg/hr. Good for asthma`],[`Dexmedetomidine gtt`,`0.2-1.4 mcg/kg/hr`,`IV infusion`,`No resp depression; causes bradycardia + hypotension`],[`Rocuronium gtt`,`10-12 mcg/kg/min`,`IV infusion`,`If continued paralysis needed — only with adequate sedation`]]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`Equipment sizing`}),(0,l.jsxs)(`div`,{className:`grid grid-cols-1 md:grid-cols-2 gap-3 text-xs`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-muted/40 p-3`,children:d?(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`ETT (uncuffed):`}),` `,f,` mm`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`ETT (cuffed):`}),` `,p,` mm`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Depth at lip:`}),` ~`,m,` cm`]})]}):(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`div`,{children:(0,l.jsx)(`em`,{children:`Enter age for ETT / blade sizing.`})}),(0,l.jsx)(`div`,{children:`ETT (uncuffed) = (age/4) + 4`}),(0,l.jsx)(`div`,{children:`ETT (cuffed) = (age/4) + 3.5`}),(0,l.jsx)(`div`,{children:`Depth = ETT size × 3`})]})}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Laryngoscope blade:`}),` `,h]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`LMA size:`}),` `,g]}),(0,l.jsx)(`div`,{children:`OPA = corner mouth → angle mandible`}),(0,l.jsx)(`div`,{children:`NPA = tip nose → tragus`})]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 md:col-span-2`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Suction catheter (Fr):`}),` ETT size × 2`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`NG tube:`}),` ETT × 2`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Chest tube:`}),` 4 × ETT`]})]})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`Ventilator — starting settings`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-xs space-y-1`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Mode:`}),` Volume or pressure control`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Tidal volume:`}),` 6-8 mL/kg (= `,v.value,`-`,y.value,` mL). Use lower (4-6 mL/kg) for ARDS.`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`Rate:`}),` Infant 25-30, Child 15-25, Adolescent 12-16`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`PEEP:`}),` 5 cmH₂O (↑ for oxygenation problems)`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`FiO₂:`}),` Start 100%, wean to SpO₂ 92-97%`]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`strong`,{children:`I:E ratio:`}),` 1:2 (1:3-4 for obstructive disease)`]})]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`Harriet Lane Handbook 23rd ed · PALS 2020. Always confirm doses against institutional protocols.`})]}):(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see doses.`})]})}function R(){let[e,t]=(0,c.useState)(``),n=Number.parseFloat(e),r=Number.isFinite(n)&&n>0;function i(e,t,n,r){return(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:e}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:t})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:n}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,dangerouslySetInnerHTML:{__html:r}})]})}let a=r?[i(`Lorazepam`,s(n,.05,2).label,`PO`,`0.05 mg/kg. May repeat in 30 min.`),i(`Midazolam`,s(n,.5,10).label,`PO`,`0.5 mg/kg (max 10 mg)`),i(`Midazolam`,s(n,.3,10).label,`IN (5 mg/mL)`,`0.3 mg/kg split between nares (max 10 mg)`),i(`Olanzapine (ODT)`,n<30?`2.5-5 mg`:`5-10 mg`,`PO / ODT`,`Age ≥6 yr. Avoid IM + benzo combo (risk of resp depression).`),i(`Diphenhydramine`,s(n,1,50).label,`PO`,`1 mg/kg. Adjunct only; sedating.`)]:null,o=r?[i(`Midazolam`,s(n,.1,5).label,`IV / IM`,`0.05-0.1 mg/kg IV, 0.1-0.15 mg/kg IM (max 10 mg)`),i(`Lorazepam`,s(n,.1,4).label,`IV / IM`,`0.05-0.1 mg/kg (max 4 mg). May cause resp depression.`),i(`Haloperidol`,n<40?`0.025-0.075 mg/kg = ${Math.round(n*.05*100)/100} mg`:`2.5-5 mg`,`IM / IV`,`Avoid <3 yr. Risk: QT, EPS, NMS. ECG if repeated.`),i(`Olanzapine`,n<40?`2.5-5 mg`:`5-10 mg`,`IM`,`Avoid benzo co-administration (resp depression, hypotension)`),i(`Ketamine`,s(n,4,500).label,`IM`,`4-5 mg/kg IM (rescue for severe excited delirium). Monitor airway.`),i(`Droperidol`,`0.03-0.07 mg/kg = ${Math.round(n*.05*100)/100} mg`,`IM / IV`,`Effective but QT concern — get ECG.`)]:null;return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-agitation`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Agitation`}),(0,l.jsx)(A,{id:`agit-wt`,value:e,onChange:t,testid:`agit-weight`}),r?(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-purple-500 bg-purple-50 dark:bg-purple-950/30 p-3 text-sm font-semibold text-purple-900 dark:text-purple-100`,children:[`Agitation management — `,n,` kg`]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-green-500 bg-green-50 dark:bg-green-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-green-800 dark:text-green-200`,children:`Step 1 — Non-pharmacologic`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Dim lights, quiet room, familiar caregiver present, reduce stimulation. Rule out hypoglycemia, hypoxia, pain, ↑ICP, toxic ingestion, infection.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-blue-800 dark:text-blue-200`,children:`Step 2 — Oral / intranasal (cooperative)`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`First-line for moderate agitation if the patient will accept PO/IN.`})]}),(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:a})]})}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-amber-500 bg-amber-50 dark:bg-amber-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-amber-800 dark:text-amber-200`,children:`Step 3 — IM / IV (severe, uncooperative, or safety risk)`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Require continuous monitoring. Consider restraints only as last resort.`})]}),(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:o})]})}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Monitoring:`}),` Continuous SpO₂ + HR after parenteral sedation. Have airway equipment, flumazenil, naloxone, and IV access ready.`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`AAP Clinical Report on Pediatric Agitation · ACEP Guidelines for Acute Agitation.`})]}):(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see doses.`})]})}function z(){let[e,t]=(0,c.useState)(``),n=Number.parseFloat(e),r=Number.isFinite(n)&&n>0,i=(e,t,i=`mg`)=>r?s(n,e,t,i):null,a=r?n<15?`2 mg`:n<30?`4 mg`:`8 mg`:null;return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-antiemetics`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Antiemetics`}),(0,l.jsx)(A,{id:`emet-wt`,value:e,onChange:t,testid:`emet-weight`}),r?(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold text-blue-900 dark:text-blue-100`,children:[`Antiemetic doses — `,n,` kg`]}),(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsxs)(`tbody`,{children:[(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Ondansetron`}),(0,l.jsxs)(`td`,{className:k+` text-xs`,children:[a,` (weight band) OR `,(0,l.jsx)(j,{label:i(.15,8).label})]}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`PO / ODT / IV`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`First-line. Max single 8 mg. Repeat q8h. QT prolongation — avoid with other QT drugs. <6 mo: limited data.`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Metoclopramide`}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:i(.15,10).label})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`IV / IM / PO`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`0.1-0.15 mg/kg (max 10 mg). Give with diphenhydramine to prevent EPS / dystonia.`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Dimenhydrinate`}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:i(1.25,50).label})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`PO / IV / IM / PR`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`1.25 mg/kg (max 50 mg) q6h. ≥2 yr.`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Diphenhydramine`}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:i(1,50).label})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`PO / IV / IM`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`1 mg/kg (max 50 mg) q6h. Adjunct, sedating.`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Promethazine`}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:i(.25,25).label})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`PO / IV / IM`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,dangerouslySetInnerHTML:{__html:`0.25-1 mg/kg. <strong>CONTRAINDICATED <2 yr</strong> (resp depression). Tissue injury if IV extrav.`}})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Dexamethasone`}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:i(.15,10).label})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`IV / PO`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`Adjunct, esp. chemo-induced. 0.15 mg/kg (max 10 mg).`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Scopolamine patch`}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`1.5 mg patch`}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`Transdermal`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`≥12 yr. Motion sickness. Apply 4h before exposure.`})]})]})]})}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Pearls:`}),` Ondansetron is first-line in ED for acute gastroenteritis vomiting — single PO/ODT dose increases oral rehydration success. Avoid anticholinergics + opioid combinations. Check QTc if stacking ondansetron + other QT drugs.`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`AAP gastroenteritis guidance · WHO essential medicines · Lexicomp.`})]}):(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see doses.`})]})}var B={neonate:{sepsis:{first:`Ampicillin + gentamicin`,alt:`Add cefotaxime if meningitis suspected or gram-neg concern`,duration:`7-10 days; 21 days if confirmed meningitis`,notes:`Cover GBS, E. coli, Listeria. Add acyclovir if HSV risk (maternal lesions, vesicles, seizures).`},meningitis:{first:`Ampicillin + cefotaxime (or gentamicin) + acyclovir`,alt:`Add vancomycin if gram-positive cocci`,duration:`14-21 days depending on organism`,notes:`HSV coverage essential. LP + HSV PCR.`},pna:{first:`Ampicillin + gentamicin`,alt:`Add cefotaxime for gram-neg`,duration:`7-10 days`,notes:`Same as sepsis coverage.`},uti:{first:`Ampicillin + gentamicin`,alt:`Cefotaxime if sensitivities known`,duration:`10-14 days`,notes:`Evaluate for sepsis. Renal US and VCUG workup.`},skin:{first:`Ampicillin + gentamicin`,alt:`Add vancomycin if MRSA risk`,duration:`7-10 days`,notes:`Omphalitis, mastitis — broad coverage.`},ent:{first:`Discuss with infectious diseases`,alt:`—`,duration:`—`,notes:`Rare in neonates. Any ear/throat infection warrants sepsis eval.`},neutropenic:{first:`Cefepime or piperacillin-tazobactam`,alt:`Add vancomycin if indwelling line, severe mucositis, or MRSA`,duration:`Until ANC recovery + afebrile ≥48h`,notes:`Oncology/ID consult.`},ic:{first:`Ampicillin + gentamicin + metronidazole`,alt:`Or piperacillin-tazobactam`,duration:`7-14 days`,notes:`NEC: add metronidazole/clindamycin for anaerobes.`},bone:{first:`Ampicillin + gentamicin`,alt:`Vancomycin if MRSA risk`,duration:`3-6 weeks (IV then PO)`,notes:`Usually hematogenous. S. aureus, GBS, E. coli.`}},infant:{sepsis:{first:`Ampicillin + ceftriaxone (or gentamicin)`,alt:`+ vancomycin if MRSA / severe`,duration:`7-10 days`,notes:`Add acyclovir if HSV suspected (<6 wks). Fever in <90 days requires workup.`},meningitis:{first:`Ceftriaxone + vancomycin (± ampicillin if <6 wks for Listeria)`,alt:`+ acyclovir if HSV`,duration:`10-14 days (longer for Listeria/gram-neg)`,notes:`Dexamethasone if H. influenzae suspected.`},pna:{first:`Ampicillin (or ceftriaxone)`,alt:`Add azithromycin if atypical`,duration:`7-10 days`,notes:`S. pneumoniae most common. RSV/viral often primary.`},uti:{first:`Ceftriaxone or cefotaxime`,alt:`Ampicillin + gentamicin`,duration:`10-14 days`,notes:`US kidney/bladder if first febrile UTI.`},skin:{first:`Cefazolin or clindamycin`,alt:`Vancomycin if MRSA risk`,duration:`7-10 days`,notes:`Consider MRSA if purulent or local resistance >10%.`},ent:{first:`Amoxicillin (90 mg/kg/day) for AOM`,alt:`Amox-clav if recent abx/treatment failure`,duration:`AOM 10 days <2 yr; 7 days ≥2 yr`,notes:`Observe mild AOM if >6 mo and no severe features.`},neutropenic:{first:`Cefepime or piperacillin-tazobactam`,alt:`+ vancomycin for severe/mucositis/line`,duration:`Until ANC recovery + afebrile`,notes:`Oncology/ID consult.`},ic:{first:`Ceftriaxone + metronidazole`,alt:`Piperacillin-tazobactam`,duration:`5-7 days (uncomplicated), longer for complicated`,notes:`Appendicitis — surgical consult.`},bone:{first:`Cefazolin ± vancomycin`,alt:`Clindamycin`,duration:`3-4 weeks (IV then PO transition)`,notes:`S. aureus most common. Kingella in <4 yr.`}},child:{sepsis:{first:`Ceftriaxone + vancomycin`,alt:`Piperacillin-tazobactam if intra-abdominal`,duration:`7-14 days`,notes:`Expand if specific source. Add antifungal if prolonged neutropenia.`},meningitis:{first:`Ceftriaxone + vancomycin`,alt:`+ dexamethasone (Hib coverage)`,duration:`10-14 days`,notes:`Lumbar puncture. Dexamethasone 0.15 mg/kg q6h x 4 days.`},pna:{first:`Ampicillin OR amoxicillin (high dose)`,alt:`Ceftriaxone if hospitalized; add azithromycin for atypical`,duration:`5-7 days (uncomplicated)`,notes:`Mycoplasma if >5 yr. Consider viral causes.`},uti:{first:`Cephalexin or TMP-SMX (PO)`,alt:`Ceftriaxone if ill`,duration:`7-10 days (10-14 if pyelo)`,notes:`Culture-guided de-escalation.`},skin:{first:`Cephalexin or clindamycin`,alt:`TMP-SMX or doxycycline if MRSA`,duration:`5-10 days`,notes:`Abscess — incision & drainage primary tx.`},ent:{first:`Amoxicillin 90 mg/kg/day (AOM); Penicillin V for strep pharyngitis`,alt:`Amox-clav; cephalexin if non-anaphylactic PCN allergy`,duration:`AOM 5-10 days; strep 10 days`,notes:`Strep pharyngitis dose: PCN V 250 mg BID-TID (<27 kg) or 500 mg BID (≥27 kg).`},neutropenic:{first:`Cefepime OR piperacillin-tazobactam`,alt:`+ vancomycin`,duration:`Until ANC recovery + afebrile`,notes:`Add empiric antifungal if fever >4-7 days.`},ic:{first:`Ceftriaxone + metronidazole`,alt:`Piperacillin-tazobactam`,duration:`5-7 days (uncomplicated appendicitis)`,notes:`Surgical consult.`},bone:{first:`Cefazolin ± vancomycin`,alt:`Clindamycin`,duration:`3-4 weeks total`,notes:`S. aureus, group A strep. Consider MRSA if severe.`}}},V={neonate:`Neonate (0-28 d)`,infant:`Infant (1-3 mo)`,child:`Child (>3 mo)`},H=[[`sepsis`,`Sepsis / bacteremia`],[`meningitis`,`Meningitis`],[`pna`,`Pneumonia`],[`uti`,`Urinary tract infection`],[`skin`,`Skin / soft tissue`],[`ent`,`Ear / throat (ENT)`],[`neutropenic`,`Febrile neutropenia`],[`ic`,`Intra-abdominal`],[`bone`,`Bone / joint`]];function U(){let[e,t]=(0,c.useState)(`child`),[n,r]=(0,c.useState)(`sepsis`),i=B[e][n];return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-antimicrobials`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Antimicrobials (empirical)`}),(0,l.jsxs)(`div`,{className:`grid grid-cols-1 sm:grid-cols-2 gap-3 max-w-xl`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{htmlFor:`abx-age`,className:D,children:`Age band`}),(0,l.jsx)(`select`,{id:`abx-age`,className:E,value:e,onChange:e=>t(e.target.value),"data-testid":`abx-age`,children:Object.entries(V).map(([e,t])=>(0,l.jsx)(`option`,{value:e,children:t},e))})]}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{htmlFor:`abx-infection`,className:D,children:`Infection`}),(0,l.jsx)(`select`,{id:`abx-infection`,className:E,value:n,onChange:e=>r(e.target.value),"data-testid":`abx-infection`,children:H.map(([e,t])=>(0,l.jsx)(`option`,{value:e,children:t},e))})]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold text-blue-900 dark:text-blue-100`,children:[V[e],` — `,H.find(([e])=>e===n)?.[1]]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-green-50 dark:bg-green-950/30 p-3 text-sm`,children:[(0,l.jsx)(`strong`,{className:`text-green-800 dark:text-green-200`,children:`First-line:`}),` `,i.first]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-sm`,children:[(0,l.jsx)(`strong`,{children:`Alternative / add:`}),` `,i.alt]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-sm`,children:[(0,l.jsx)(`strong`,{children:`Duration:`}),` `,i.duration]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Notes:`}),` `,i.notes]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`AAP Red Book · IDSA guidelines · Harriet Lane. Always tailor to local resistance patterns and culture results.`})]})}function W(){let[e,t]=(0,c.useState)(``),n=Number.parseFloat(e),r=Number.isFinite(n)&&n>0,i=r?Math.round(n*20):null;return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-trauma`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Trauma — primary survey + MTP`}),(0,l.jsx)(A,{id:`trauma-wt`,value:e,onChange:t,testid:`trauma-weight`}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-2`,children:`Primary Survey — ABCDE`}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-destructive bg-red-50 dark:bg-red-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-destructive`,children:`A — Airway + c-spine`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:[`Maintain airway (jaw thrust, suction). `,(0,l.jsx)(`strong`,{children:`Manual inline stabilization`}),`; apply collar. Intubate if GCS ≤8, inadequate airway, or impending compromise. Avoid succinylcholine if burn/crush/prolonged immobilization.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-amber-500 bg-amber-50 dark:bg-amber-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-amber-800 dark:text-amber-200`,children:`B — Breathing`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`SpO₂, bilateral breath sounds, chest wall integrity. Identify tension PTX (needle decompression), open PTX (3-sided dressing), flail chest, massive hemothorax.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-green-500 bg-green-50 dark:bg-green-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-green-800 dark:text-green-200`,children:`C — Circulation`}),(0,l.jsxs)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:[`Two large-bore IVs / IO. Control hemorrhage (direct pressure, tourniquet, pelvic binder).`,` `,r?(0,l.jsxs)(l.Fragment,{children:[`NS or LR 20 mL/kg = `,(0,l.jsxs)(`strong`,{children:[i,` mL`]}),` bolus.`]}):(0,l.jsx)(l.Fragment,{children:`NS/LR 20 mL/kg bolus.`}),` `,`Consider blood after 40-60 mL/kg crystalloid or in Class III shock.`]})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-blue-500 bg-blue-50 dark:bg-blue-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-blue-800 dark:text-blue-200`,children:`D — Disability`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`GCS, pupils, glucose, gross motor. Consider ↑ICP (head up 30°, mannitol 0.5-1 g/kg or hypertonic saline 3% 3-5 mL/kg).`})]}),(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 border-violet-500 bg-violet-50 dark:bg-violet-950/30 p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold text-violet-800 dark:text-violet-200`,children:`E — Exposure + environment`}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground mt-1`,children:`Fully expose; prevent hypothermia (warm blankets, fluids).`})]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`Massive Transfusion Protocol (MTP)`}),(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsxs)(`tbody`,{children:[(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Ratio`}),(0,l.jsx)(`td`,{className:k,children:`1:1:1 (pRBC : FFP : platelets)`}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`—`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`Activate early if ≥40 mL/kg transfused or ongoing hemorrhage. Avoid excessive crystalloid.`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Tranexamic acid (TXA)`}),(0,l.jsx)(`td`,{className:k,children:`15 mg/kg IV (max 1 g) over 10 min → 2 mg/kg/hr × 8h`}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`IV`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`Within 3 hr of injury. CRASH-2 / MATIC.`})]}),(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:`Calcium`}),(0,l.jsx)(`td`,{className:k,children:`20 mg/kg CaCl or 60 mg/kg Ca-gluconate IV per unit citrated blood`}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:`IV`}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:`Citrated blood chelates calcium.`})]})]})]})}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`C-spine clearance (NEXUS / CCR)`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-xs`,children:[`Pediatric c-spine decision tools are imperfect. `,(0,l.jsx)(`strong`,{children:`Imaging if any:`}),` focal neurologic deficit, altered mental status, neck pain / tenderness, torticollis, substantial torso injury, high-risk mechanism (diving, MVC >55 mph, fall >10 ft). Plain films + CT if positive or equivocal.`]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`Pediatric shock — signs`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-red-50 dark:bg-red-950/30 p-3 text-xs text-red-900 dark:text-red-200`,children:[`Children compensate well — `,(0,l.jsx)(`strong`,{children:`hypotension is a late finding`}),`. Early signs: tachycardia, cool extremities, weak peripheral pulses, prolonged cap refill (>3 sec), narrowed pulse pressure, altered mentation. Minimum SBP = 70 + (2 × age in years) for ages 1-10.`]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold mt-3`,children:`Secondary survey — AMPLE + head-to-toe`}),(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-xs`,children:[(0,l.jsx)(`strong`,{children:`AMPLE:`}),` Allergies, Medications, Past history, Last meal, Events of injury. Head-to-toe exam; log-roll for back; digital rectal; neurovascular checks of all extremities.`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`ATLS 10th ed · PALS 2020 · PECARN c-spine rule · CRASH-2 trial (TXA).`})]})}var G=[{name:`Ketamine IV`,display:`Ketamine`,perKgLow:1.5,perKgHigh:2,maxLow:100,maxHigh:150,unit:`mg`,route:`IV`,onset:`1 min`,duration:`15-30 min`,notes:`Dissociative. Preserves airway reflexes.`},{name:`Ketamine IM`,display:null,perKgLow:4,perKgHigh:5,maxLow:300,maxHigh:400,unit:`mg`,route:`IM`,onset:`3-5 min`,duration:`30-60 min`,notes:`Give atropine 0.01 mg/kg to reduce secretions.`},{name:`Midazolam IV`,display:`Midazolam`,perKgLow:.05,perKgHigh:.1,maxLow:2,maxHigh:5,unit:`mg`,route:`IV`,onset:`2-3 min`,duration:`30-60 min`,notes:`Anxiolysis. Titrate q3-5 min.`},{name:`Midazolam IN/PO`,display:null,perKg:.5,max:20,unit:`mg`,route:`IN/PO`,onset:`10-15 min`,duration:`30-60 min`,notes:`IN (max 10 mg / naris) or PO (max 20 mg).`},{name:`Propofol`,display:`Propofol`,perKg:1,max:40,unit:`mg`,route:`IV`,onset:`30 sec`,duration:`5-10 min`,notes:`Short procedures. Causes apnea — manage airway.`},{name:`Fentanyl IV`,display:`Fentanyl`,perKg:1,max:100,unit:`mcg`,route:`IV`,onset:`2-3 min`,duration:`30-60 min`,notes:`Analgesic. Often combined with midazolam.`},{name:`Fentanyl IN`,display:null,perKg:2,max:100,unit:`mcg`,route:`IN`,onset:`5-10 min`,duration:`30-60 min`,notes:`Intranasal.`},{name:`Nitrous oxide`,display:`Nitrous oxide`,doseDisplay:`50:50 or 70:30 mix`,unit:`mix`,route:`Inhaled`,onset:`2-5 min`,duration:`5 min off`,notes:`Self-administered via demand valve. Anxiolysis + mild analgesia.`},{name:`Dexmedetomidine IN`,display:`Dexmedetomidine`,perKgLow:2,perKgHigh:3,maxLow:100,maxHigh:null,unit:`mcg`,route:`IN`,onset:`15-30 min`,duration:`60-90 min`,notes:`Intranasal. No respiratory depression. Good for imaging.`},{name:`Naloxone`,display:`Naloxone`,perKg:.1,max:2,unit:`mg`,route:`IV/IM/IN`,reverses:`Opioids (fentanyl, morphine)`,notes:`Max 2 mg. Repeat q2-3 min. Duration shorter than opioids — monitor for re-sedation.`},{name:`Flumazenil`,display:`Flumazenil`,perKg:.01,max:.2,unit:`mg`,route:`IV`,reverses:`Benzodiazepines (midazolam)`,notes:`Max 0.2 mg single dose. Repeat q1 min to max 1 mg total. Risk of seizures — use cautiously.`}];function K(e,t){if(t.doseDisplay)return t.doseDisplay;let n=t.unit===`mcg`?` mcg`:t.unit===`mix`?``:` mg`,r=t.unit===`mcg`?`mcg`:`mg`;if(t.perKgLow!=null){let i=s(e,t.perKgLow,t.maxLow??null).value;return t.perKgHigh==null?`${i}${n} (${t.perKgLow} ${r}/kg)`:`${i}-${s(e,t.perKgHigh,t.maxHigh??null).value}${n} (${t.perKgLow}-${t.perKgHigh} ${r}/kg)`}return t.perKg==null?``:`${s(e,t.perKg,t.max??null).value}${n} (${t.perKg} ${r}/kg)`}function q(){let[e,t]=(0,c.useState)(``),n=Number.parseFloat(e),r=Number.isFinite(n)&&n>0,i=G.filter(e=>!e.reverses),a=G.filter(e=>e.reverses);function o({dg:e}){return(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:e.display??``}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:K(n,e)})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:e.route}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:e.onset??``}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:e.duration??``}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:e.notes})]})}function s({dg:e}){return(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:e.display}),(0,l.jsx)(`td`,{className:k,children:(0,l.jsx)(j,{label:K(n,e)})}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:e.route}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:e.reverses}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,children:e.notes})]})}return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-sedation`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Procedural Sedation`}),(0,l.jsx)(A,{id:`sed-wt`,value:e,onChange:t,testid:`sed-weight`}),r?(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)(`div`,{className:`rounded-md border-2 border-purple-500 bg-purple-50 dark:bg-purple-950/30 p-3 text-sm font-semibold text-purple-900 dark:text-purple-100`,children:[`Procedural Sedation — `,n,` kg patient`]}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold`,children:`Sedation Agents`}),(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Onset`}),(0,l.jsx)(`th`,{className:O,children:`Duration`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:i.map(e=>(0,l.jsx)(o,{dg:e},e.name))})]})}),(0,l.jsx)(`h3`,{className:`text-sm font-semibold text-destructive`,children:`Reversal Agents`}),(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{className:`bg-red-50 dark:bg-red-950/30`,children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Reverses`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:a.map(e=>(0,l.jsx)(s,{dg:e},e.name))})]})}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Pre-sedation checklist:`}),` NPO status (2h clear liquids, 6h solids), consent, monitoring equipment (pulse ox, capnography, BP), resuscitation equipment at bedside, suction ready, IV access. Minimum monitoring: continuous SpO₂, HR, capnography. Provider capable of managing airway must be present.`]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`AAP Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation · ASA Practice Guidelines for Sedation and Analgesia by Non-Anesthesiologists.`})]}):(0,l.jsx)(`p`,{className:`text-xs text-destructive`,children:`Enter weight (kg) to see doses.`})]})}var J=[[`approach`,`General approach (stabilize → toxidrome → decon → antidote)`],[`acetaminophen`,`Acetaminophen overdose`],[`opioids`,`Opioid overdose`],[`iron`,`Iron overdose`],[`tca`,`Tricyclic antidepressant (TCA) overdose`],[`bbccb`,`β-blocker / CCB overdose`],[`benzo`,`Benzodiazepine overdose`],[`organo`,`Organophosphate / carbamate poisoning`],[`salicylate`,`Salicylate overdose`],[`etoh`,`Toxic alcohols (methanol / ethylene glycol)`],[`dialyzable`,`Dialyzable drugs (ISTUMBLE)`]];function Y(){let[e,t]=(0,c.useState)(``),[n,r]=(0,c.useState)(`approach`),i=Number.parseFloat(e),a=Number.isFinite(i)&&i>0,o=(e,t,n=`mg`)=>a?s(i,e,t,n).value:null;function u({color:e,title:t,body:n}){return(0,l.jsxs)(`div`,{className:`rounded-md border-l-4 ${e} p-3 text-sm`,children:[(0,l.jsx)(`div`,{className:`font-semibold mb-1`,children:t}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground`,children:n})]})}function d({drug:e,dose:t,route:n,notes:r}){return(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`td`,{className:k+` font-semibold`,children:e}),(0,l.jsx)(`td`,{className:k,children:t}),(0,l.jsx)(`td`,{className:k+` text-xs`,children:n}),(0,l.jsx)(`td`,{className:k+` text-xs text-muted-foreground`,dangerouslySetInnerHTML:{__html:r}})]})}function f({children:e}){return(0,l.jsx)(`div`,{className:`overflow-x-auto`,children:(0,l.jsxs)(`table`,{className:`w-full text-sm`,children:[(0,l.jsx)(`thead`,{children:(0,l.jsxs)(`tr`,{children:[(0,l.jsx)(`th`,{className:O,children:`Drug`}),(0,l.jsx)(`th`,{className:O,children:`Dose`}),(0,l.jsx)(`th`,{className:O,children:`Route`}),(0,l.jsx)(`th`,{className:O,children:`Notes`})]})}),(0,l.jsx)(`tbody`,{children:e})]})})}return(0,l.jsxs)(`section`,{className:T,"data-testid":`bedside-panel-toxicology`,children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Toxicology`}),(0,l.jsxs)(`div`,{className:`grid grid-cols-1 sm:grid-cols-2 gap-3 max-w-xl`,children:[(0,l.jsx)(A,{id:`tox-wt`,value:e,onChange:t,testid:`tox-weight`}),(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`label`,{htmlFor:`tox-topic`,className:D,children:`Topic`}),(0,l.jsx)(`select`,{id:`tox-topic`,className:E,value:n,onChange:e=>r(e.target.value),"data-testid":`tox-topic`,children:J.map(([e,t])=>(0,l.jsx)(`option`,{value:e,children:t},e))})]})]}),n===`approach`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(u,{color:`border-blue-500 bg-blue-50 dark:bg-blue-950/30`,title:`1. Stabilize (ABCDE)`,body:(0,l.jsx)(l.Fragment,{children:`Airway, breathing, circulation, disability (glucose, pupils, GCS), exposure. Naloxone if depressed LOC + resp depression. Dextrose if hypoglycemic. Thiamine in select cases.`})}),(0,l.jsx)(u,{color:`border-purple-500 bg-purple-50 dark:bg-purple-950/30`,title:`2. Identify toxidrome`,body:(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`strong`,{children:`Sympathomimetic:`}),` HTN, tachy, mydriasis, diaphoresis (cocaine, meth). `,(0,l.jsx)(`strong`,{children:`Anticholinergic:`}),` hot/dry, mydriasis, tachy, delirium (antihistamines, TCAs). `,(0,l.jsx)(`strong`,{children:`Cholinergic:`}),` SLUDGE-M, miosis (organophosphates). `,(0,l.jsx)(`strong`,{children:`Opioid:`}),` miosis, resp depression, ↓LOC. `,(0,l.jsx)(`strong`,{children:`Sedative-hypnotic:`}),` ↓LOC, normal/low vitals.`]})}),(0,l.jsx)(u,{color:`border-amber-500 bg-amber-50 dark:bg-amber-950/30`,title:`3. Decontamination`,body:(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`strong`,{children:`Activated charcoal`}),` 1 g/kg PO (max 50 g): within 1h of ingestion, intact airway, ingestion adsorbed (not Li, metals, alcohols). Avoid caustics/hydrocarbons. `,(0,l.jsx)(`strong`,{children:`Whole bowel irrigation:`}),` PEG for metals/iron/lithium/sustained release. `,(0,l.jsx)(`strong`,{children:`Gastric lavage:`}),` rarely indicated. `,(0,l.jsx)(`strong`,{children:`Ipecac:`}),` no longer recommended.`]})}),(0,l.jsx)(u,{color:`border-green-500 bg-green-50 dark:bg-green-950/30`,title:`4. Enhance elimination`,body:(0,l.jsxs)(l.Fragment,{children:[(0,l.jsx)(`strong`,{children:`Urinary alkalinization`}),` (salicylates, phenobarbital). `,(0,l.jsx)(`strong`,{children:`Hemodialysis`}),` (see ISTUMBLE). `,(0,l.jsx)(`strong`,{children:`Lipid emulsion`}),` for lipid-soluble drug toxicity (LA, CCB, TCA).`]})}),(0,l.jsx)(u,{color:`border-destructive bg-red-50 dark:bg-red-950/30`,title:`5. Antidotes`,body:(0,l.jsxs)(l.Fragment,{children:[`See topic list. `,(0,l.jsx)(`strong`,{children:`Contact Poison Center`}),` (US: 1-800-222-1222) early for any significant exposure.`]})})]}),n===`acetaminophen`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`Acetaminophen overdose`}),(0,l.jsx)(`p`,{className:`text-sm`,children:`Acute toxic dose: >150 mg/kg (or 7.5 g total) single ingestion. Hepatotoxic after 24h; AST/ALT peak day 3-4.`}),(0,l.jsxs)(`p`,{className:`text-sm`,children:[(0,l.jsx)(`strong`,{children:`Diagnosis:`}),` Draw level at 4h post-ingestion (or on arrival if >4h). Plot on `,(0,l.jsx)(`strong`,{children:`Rumack-Matthew nomogram`}),` (treatment line at 150 mcg/mL at 4h).`]}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{drug:`N-acetylcysteine (NAC) — IV`,dose:`150 mg/kg over 1h → 50 mg/kg over 4h → 100 mg/kg over 16h (21h total)`,route:`IV`,notes:`Total 300 mg/kg. Most effective if started <8h post-ingestion.`}),(0,l.jsx)(d,{drug:`N-acetylcysteine — PO`,dose:`140 mg/kg load, then 70 mg/kg q4h × 17 doses`,route:`PO`,notes:`Alternative to IV. Unpleasant taste — often with juice.`}),(0,l.jsx)(d,{drug:`Activated charcoal`,dose:`1 g/kg (max 50 g)`,route:`PO`,notes:`If within 1-2h of ingestion and airway protected.`})]}),a&&(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-3 text-xs`,children:[(0,l.jsxs)(`strong`,{children:[`For `,i,` kg:`]}),` IV loading = `,o(150,null),` mg over 1h `,(0,l.jsx)(`span`,{className:`text-muted-foreground`,children:`(150 mg/kg)`}),`; 2nd bag = `,o(50,null),` mg over 4h `,(0,l.jsx)(`span`,{className:`text-muted-foreground`,children:`(50 mg/kg)`}),`; 3rd bag = `,o(100,null),` mg over 16h `,(0,l.jsx)(`span`,{className:`text-muted-foreground`,children:`(100 mg/kg)`}),`. `,(0,l.jsx)(`em`,{children:`Total 300 mg/kg.`})]})]}),n===`opioids`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`Opioid overdose`}),(0,l.jsxs)(`p`,{className:`text-sm`,children:[`Triad: `,(0,l.jsx)(`strong`,{children:`miosis + respiratory depression + ↓ LOC`}),`. Fentanyl / synthetics may require repeated/higher doses.`]}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{drug:`Naloxone (initial)`,dose:a?`0.01-0.1 mg/kg = ${o(.01,null)}-${o(.1,null)} mg`:`0.01-0.1 mg/kg`,route:`IV / IM / IN / IO`,notes:`Start low if chronic opioid use (avoid withdrawal). Titrate to respiratory effort, not consciousness.`}),(0,l.jsx)(d,{drug:`Naloxone (full reversal)`,dose:`2 mg IV/IM/IN`,route:`IV / IM / IN`,notes:`If no chronic use and severe resp depression. Repeat q2-3 min.`}),(0,l.jsx)(d,{drug:`Naloxone infusion`,dose:`2/3 of effective bolus per hour`,route:`IV`,notes:`For long-acting opioids (methadone, fentanyl patch, sustained release)`})]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[`Observe ≥4h after last dose; longer for long-acting agents. Duration of naloxone (30-90 min) is shorter than most opioids — `,(0,l.jsx)(`strong`,{children:`re-sedation is common`}),`.`]})]}),n===`iron`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`Iron overdose`}),(0,l.jsxs)(`p`,{className:`text-sm`,children:[`Toxic dose: elemental Fe ≥20 mg/kg. Severe ≥60 mg/kg. `,(0,l.jsx)(`strong`,{children:`Charcoal does NOT bind iron.`})]}),(0,l.jsxs)(`p`,{className:`text-sm`,children:[(0,l.jsx)(`strong`,{children:`Stages:`}),` 1) GI (0-6h: vomiting, bloody diarrhea); 2) Latent (6-24h); 3) Shock/metabolic acidosis (12-24h); 4) Hepatotoxicity (2-5d); 5) Gastric scarring (2-8 wk).`]}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{drug:`Whole bowel irrigation`,dose:`PEG-ES 25-40 mL/kg/hr`,route:`NG`,notes:`For radiopaque pills on KUB or ingested sustained-release iron.`}),(0,l.jsx)(d,{drug:`Deferoxamine`,dose:`15 mg/kg/hr IV infusion`,route:`IV`,notes:`Max 6-8 g/day. Indications: shock, metabolic acidosis, Fe >500 mcg/dL, or severe symptoms. Urine turns 'vin rosé' color.`})]}),(0,l.jsx)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:`Iron level at 4-6h. <350 usually asymptomatic; 350-500 mild; >500 severe. Consider KUB for radiopaque pills.`})]}),n===`tca`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`TCA overdose`}),(0,l.jsxs)(`p`,{className:`text-sm`,children:[`Anticholinergic + Na-channel blockade. `,(0,l.jsx)(`strong`,{children:`Risks:`}),` seizure, VT/VF, hypotension, coma. ECG: QRS >100 ms or R in aVR >3 mm predicts toxicity.`]}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{drug:`Sodium bicarbonate 8.4%`,dose:`1-2 mEq/kg IV bolus → infusion`,route:`IV`,notes:`Goal pH 7.45-7.55 and narrowing QRS. Repeat bolus for QRS widening, hypotension, or arrhythmia.`}),(0,l.jsx)(d,{drug:`Mg sulfate`,dose:a?`${o(50,2e3)} mg`:`25-50 mg/kg (max 2 g)`,route:`IV over 10 min`,notes:`For torsades.`}),(0,l.jsx)(d,{drug:`IV lipid emulsion 20%`,dose:`1.5 mL/kg bolus → 0.25 mL/kg/min × 30-60 min`,route:`IV`,notes:`If refractory shock/arrest. Consult toxicology.`})]}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Avoid`}),` Class IA/IC antiarrhythmics, beta-blockers, physostigmine (risk of asystole with TCAs).`]})]}),n===`bbccb`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`β-blocker / Calcium-channel blocker overdose`}),(0,l.jsx)(`p`,{className:`text-sm`,children:`Bradycardia + hypotension. CCBs (esp. verapamil, diltiazem, amlodipine) can be lethal in small pediatric doses.`}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{drug:`IV fluids`,dose:`20 mL/kg NS bolus`,route:`IV`,notes:`Cautious — avoid volume overload`}),(0,l.jsx)(d,{drug:`Calcium chloride 10% or gluconate`,dose:`CaCl 20 mg/kg / Ca-glu 60 mg/kg`,route:`IV`,notes:`First-line for CCB. Repeat q15-20 min.`}),(0,l.jsx)(d,{drug:`Glucagon`,dose:`50 mcg/kg IV bolus → 50-150 mcg/kg/hr`,route:`IV`,notes:`β-blocker antidote. GI side effects common.`}),(0,l.jsx)(d,{drug:`High-dose insulin (HIE)`,dose:`Regular insulin 1 U/kg bolus → 0.5-2 U/kg/hr + D25% infusion`,route:`IV`,notes:`Hyperinsulinemic euglycemia therapy. Monitor K+ and glucose closely.`}),(0,l.jsx)(d,{drug:`Vasopressors`,dose:`Epi / norepi infusion`,route:`IV`,notes:`Titrate to MAP.`}),(0,l.jsx)(d,{drug:`Lipid emulsion 20%`,dose:`1.5 mL/kg → 0.25 mL/kg/min`,route:`IV`,notes:`For lipid-soluble CCBs (verapamil) if refractory.`}),(0,l.jsx)(d,{drug:`Methylene blue / ECMO`,dose:`—`,route:`—`,notes:`Rescue therapy — toxicology/ICU consult.`})]})]}),n===`benzo`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`Benzodiazepine overdose`}),(0,l.jsxs)(`p`,{className:`text-sm`,children:[`Sedation + resp depression. Usually supportive — intubation rarely needed alone. `,(0,l.jsx)(`strong`,{children:`Flumazenil caution.`})]}),(0,l.jsx)(f,{children:(0,l.jsx)(d,{drug:`Flumazenil`,dose:`0.01 mg/kg (max 0.2 mg) IV, may repeat q1 min to max 1 mg`,route:`IV`,notes:`Only for iatrogenic reversal in a benzo-naive patient with no TCAs, seizure disorder, or chronic benzo use. <strong>Can precipitate seizures.</strong>`})}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[`In real-world ingestion, `,(0,l.jsx)(`strong`,{children:`supportive care (airway, monitoring)`}),` is usually safer than flumazenil.`]})]}),n===`organo`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`Organophosphate / carbamate poisoning`}),(0,l.jsxs)(`p`,{className:`text-sm`,children:[`Cholinergic toxidrome: `,(0,l.jsx)(`strong`,{children:`SLUDGE-M`}),` (salivation, lacrimation, urination, defecation, GI distress, emesis, miosis) + muscle fasciculation, bradycardia, bronchorrhea. Decontamination critical (PPE for providers).`]}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{drug:`Atropine`,dose:`0.05 mg/kg IV, double q3-5 min until bronchial secretions dry`,route:`IV`,notes:`Endpoint = dry lungs, not dry mouth or heart rate. Can require huge doses.`}),(0,l.jsx)(d,{drug:`Pralidoxime (2-PAM)`,dose:`25-50 mg/kg IV over 30 min (max 2 g) → 10-20 mg/kg/hr`,route:`IV`,notes:`Only for organophosphates (not carbamates). Regenerates acetylcholinesterase.`}),(0,l.jsx)(d,{drug:`Diazepam / midazolam`,dose:`Standard seizure doses`,route:`IV`,notes:`For seizures or severe fasciculations.`})]})]}),n===`salicylate`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`Salicylate overdose`}),(0,l.jsx)(`p`,{className:`text-sm`,children:`Mixed respiratory alkalosis + anion gap metabolic acidosis. Tinnitus, tachypnea, diaphoresis, hyperthermia. Severe: CNS depression, seizures, pulmonary edema, cerebral edema.`}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{drug:`Fluids`,dose:`Aggressive resuscitation`,route:`IV`,notes:`Dehydration common. Avoid fluid overload (risk of pulmonary edema).`}),(0,l.jsx)(d,{drug:`Sodium bicarb`,dose:`1-2 mEq/kg IV bolus → drip`,route:`IV`,notes:`Urinary alkalinization (goal urine pH >7.5). Prevents CNS entry.`}),(0,l.jsx)(d,{drug:`Glucose`,dose:`Maintain euglycemia even if BG normal`,route:`IV`,notes:`CNS hypoglycemia despite normal serum glucose.`}),(0,l.jsx)(d,{drug:`Hemodialysis`,dose:`—`,route:`—`,notes:`For severe: altered MS, pulmonary edema, renal failure, refractory acidosis, or level >100 mg/dL acute / >60 chronic.`})]})]}),n===`etoh`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`Toxic alcohols (methanol / ethylene glycol)`}),(0,l.jsx)(`p`,{className:`text-sm`,children:`Anion gap metabolic acidosis + osmolar gap. Methanol → visual changes, blindness. Ethylene glycol → calcium oxalate crystals in urine, renal failure.`}),(0,l.jsxs)(f,{children:[(0,l.jsx)(d,{drug:`Fomepizole`,dose:`15 mg/kg IV load → 10 mg/kg q12h × 4 → 15 mg/kg q12h`,route:`IV`,notes:`First-line. Inhibits alcohol dehydrogenase.`}),(0,l.jsx)(d,{drug:`Ethanol (alternative)`,dose:`Load 600 mg/kg → maintain level 100-150 mg/dL`,route:`IV / PO`,notes:`If fomepizole unavailable. Monitor closely.`}),(0,l.jsx)(d,{drug:`Hemodialysis`,dose:`—`,route:`—`,notes:`For severe acidosis, end-organ damage, or high levels.`}),(0,l.jsx)(d,{drug:`Folate / thiamine / pyridoxine`,dose:`Standard doses`,route:`IV`,notes:`Methanol: folate. EG: thiamine + pyridoxine (divert to non-toxic metabolites).`})]})]}),n===`dialyzable`&&(0,l.jsxs)(`div`,{className:`space-y-2`,children:[(0,l.jsx)(`div`,{className:`rounded-md bg-blue-50 dark:bg-blue-950/30 p-3 text-sm font-semibold`,children:`Dialyzable drugs (ISTUMBLE)`}),(0,l.jsx)(`div`,{className:`grid grid-cols-1 sm:grid-cols-2 gap-2 text-sm`,children:[[`I`,`Isopropyl alcohol, INH`],[`S`,`Salicylates`],[`T`,`Theophylline, Toxic alcohols`],[`U`,`Uremia-related drugs`],[`M`,`Methanol, Metformin, Methotrexate`],[`B`,`Barbiturates (long-acting)`],[`L`,`Lithium`],[`E`,`Ethylene glycol`]].map(([e,t])=>(0,l.jsxs)(`div`,{className:`rounded-md bg-muted/40 p-2`,children:[(0,l.jsxs)(`strong`,{children:[e,`:`]}),` `,t]},e))}),(0,l.jsxs)(`div`,{className:`rounded-md bg-amber-50 dark:bg-amber-950/30 p-3 text-xs text-amber-900 dark:text-amber-100`,children:[(0,l.jsx)(`strong`,{children:`Poor candidates for HD:`}),` Large Vd (TCAs, digoxin, BBs), highly protein-bound (benzos, CCBs), lipid-soluble (opioids, phenothiazines). EXTRIP recommendations are evidence-based — consult toxicology.`]})]}),(0,l.jsx)(`div`,{className:`text-xs text-muted-foreground italic`,children:`Call Poison Control early: 1-800-222-1222 (US) · Refs: Goldfrank's Toxicologic Emergencies · EXTRIP workgroup.`})]})}function ee(e){switch(e){case`anaphylaxis`:return(0,l.jsx)(N,{});case`cardiac`:return(0,l.jsx)(P,{});case`seizure`:return(0,l.jsx)(I,{});case`airway`:return(0,l.jsx)(L,{});case`agitation`:return(0,l.jsx)(R,{});case`antiemetics`:return(0,l.jsx)(z,{});case`antimicrobials`:return(0,l.jsx)(U,{});case`trauma`:return(0,l.jsx)(W,{});case`sedation`:return(0,l.jsx)(q,{});case`toxicology`:return(0,l.jsx)(Y,{});case`neonatal`:return(0,l.jsx)(v,{});case`respiratory`:return(0,l.jsx)(y,{});case`ventilation`:return(0,l.jsx)(b,{});case`sepsis`:return(0,l.jsx)(x,{});case`burns`:return(0,l.jsx)(w,{});default:return null}}var te=new Set([`anaphylaxis`,`cardiac`,`seizure`,`airway`,`agitation`,`antiemetics`,`antimicrobials`,`trauma`,`sedation`,`toxicology`,`neonatal`,`respiratory`,`ventilation`,`sepsis`,`burns`]),X=`rounded-lg border border-border bg-card p-5 space-y-3`,ne=`rounded-md bg-primary text-primary-foreground px-4 py-2 text-sm font-medium`,re=`rounded-md border border-border bg-background px-4 py-2 text-sm font-medium hover:bg-muted`,Z=`block text-xs font-medium text-muted-foreground`,Q=`w-full rounded-md border border-input bg-background px-3 py-2 text-sm outline-none focus:ring-2 focus:ring-ring`,$=[{id:`neonatal`,label:`Neonatal`,icon:`👶`,summary:`GA classification, AGA/SGA/LGA, prematurity category (Fenton 2013 / WHO).`},{id:`airway`,label:`Airway / RSI`,icon:`💨`,summary:`ETT size + depth, RSI induction + paralytic dosing by weight.`},{id:`cardiac`,label:`Cardiac Arrest`,icon:`❤️`,summary:`PALS dosing (epinephrine, amiodarone, lidocaine), defibrillation J/kg.`},{id:`respiratory`,label:`Respiratory`,icon:`🫁`,summary:`Asthma, bronchiolitis, croup severity + dosing.`},{id:`ventilation`,label:`O₂ & Ventilation`,icon:`🌀`,summary:`NC / HFNC / CPAP / BiPAP flow + FiO₂ targets by age.`},{id:`seizure`,label:`Seizures`,icon:`🧠`,summary:`Benzodiazepine + second/third-line weight-based dosing.`},{id:`sepsis`,label:`Sepsis & Fever`,icon:`🦠`,summary:`Empirical antibiotics + fluid bolus dosing by weight.`},{id:`anaphylaxis`,label:`Anaphylaxis`,icon:`💉`,summary:`Epinephrine IM, IV infusion, steroid + antihistamine dosing.`},{id:`sedation`,label:`Sedation`,icon:`🛌`,summary:`Procedural sedation regimens — ketamine, propofol, midazolam.`},{id:`agitation`,label:`Agitation`,icon:`😤`,summary:`Weight-based haloperidol, olanzapine, lorazepam.`},{id:`antiemetics`,label:`Antiemetics`,icon:`💊`,summary:`Ondansetron, metoclopramide, promethazine dosing.`},{id:`antimicrobials`,label:`Antimicrobials`,icon:`🧫`,summary:`Common empirical regimens keyed to syndrome + weight.`},{id:`burns`,label:`Burns`,icon:`🔥`,summary:`TBSA % (Lund-Browder, Rule of Nines-children), Parkland fluids.`},{id:`toxicology`,label:`Toxicology`,icon:`☠️`,summary:`Common toxidromes + antidotes + decontamination windows.`},{id:`trauma`,label:`Trauma`,icon:`🩹`,summary:`PECARN, c-spine, blood-product dosing, TXA.`}];function ie(){let[e,t]=(0,c.useState)(``),[n,a]=(0,c.useState)(`apls`),[s,u]=(0,c.useState)(``),d=i(e),f=d==null?null:r(d),p=f?n===`bestguess`?f.all.bestGuess:f.all.apls:null,m=s.trim()||(p==null?``:String(p));function h(){t(``),a(`apls`),u(``)}return(0,l.jsxs)(`section`,{className:X,"data-testid":`bedside-weight-estimator`,children:[(0,l.jsxs)(`div`,{children:[(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:`Age → Weight Estimator`}),(0,l.jsx)(`p`,{className:`text-sm text-muted-foreground`,children:`Shared starting point for Bedside dosing. Uses the same APLS and Best Guess formulas as the legacy app.`})]}),(0,l.jsxs)(`div`,{className:`grid gap-3 md:grid-cols-[1.2fr_1fr_1fr_auto] md:items-end`,children:[(0,l.jsxs)(`div`,{className:`space-y-1`,children:[(0,l.jsx)(`label`,{htmlFor:`bedside-react-age`,className:Z,children:`Age`}),(0,l.jsx)(`input`,{id:`bedside-react-age`,value:e,onChange:e=>t(e.target.value),placeholder:`e.g. "18m", "3y", "2y5m"`,className:Q,"data-testid":`bedside-age-input`})]}),(0,l.jsxs)(`div`,{className:`space-y-1`,children:[(0,l.jsx)(`label`,{htmlFor:`bedside-react-formula`,className:Z,children:`Formula`}),(0,l.jsxs)(`select`,{id:`bedside-react-formula`,value:n,onChange:e=>{a(e.target.value),u(``)},className:Q,"data-testid":`bedside-formula-select`,children:[(0,l.jsx)(`option`,{value:`apls`,children:`APLS`}),(0,l.jsx)(`option`,{value:`bestguess`,children:`Best Guess`})]})]}),(0,l.jsxs)(`div`,{className:`space-y-1`,children:[(0,l.jsx)(`label`,{htmlFor:`bedside-react-weight`,className:Z,children:`Weight (kg)`}),(0,l.jsx)(`input`,{id:`bedside-react-weight`,type:`number`,min:`0.3`,step:`0.1`,value:m,onChange:e=>u(e.target.value),className:Q,"data-testid":`bedside-weight-input`})]}),(0,l.jsx)(`button`,{type:`button`,onClick:h,className:re,children:`Clear`})]}),e.trim()&&d==null?(0,l.jsx)(`div`,{className:`rounded-md border border-red-200 bg-red-50 p-3 text-sm text-red-700 dark:bg-red-950/30 dark:text-red-200`,children:`Could not parse age. Try "3y", "18 months", or "15 days".`}):null,f&&p!=null?(0,l.jsxs)(`div`,{className:`rounded-lg border border-border bg-muted/40 p-4 text-sm`,"data-testid":`bedside-estimate-result`,children:[(0,l.jsxs)(`div`,{className:`font-semibold`,children:[p,` kg estimated from `,o(d??0)]}),(0,l.jsxs)(`div`,{className:`text-muted-foreground`,children:[`APLS: `,f.all.apls,` kg · Best Guess: `,f.all.bestGuess,` kg. You can override the weight field.`]})]}):null]})}function ae({pill:e}){return(0,l.jsxs)(`section`,{className:X,"data-testid":`bedside-panel-`+e.id,children:[(0,l.jsxs)(`div`,{className:`flex items-center gap-3`,children:[(0,l.jsx)(`span`,{className:`text-2xl`,"aria-hidden":!0,children:e.icon}),(0,l.jsx)(`h2`,{className:`text-lg font-semibold`,children:e.label})]}),(0,l.jsx)(`p`,{className:`text-sm text-muted-foreground`,children:e.summary}),(0,l.jsx)(`div`,{className:`rounded-md border border-amber-300 bg-amber-50 dark:bg-amber-950/30 p-3 text-sm space-y-2`,children:(0,l.jsx)(`p`,{className:`text-amber-900 dark:text-amber-100`,children:`Weight-based calculators for this module run in the legacy viewer while the clinical data is verified for a direct React port. Open the legacy Bedside tab to use the full dosing flow.`})}),(0,l.jsx)(`a`,{href:`/#bedside`,className:ne+` inline-block`,children:`Open in legacy viewer`})]})}function oe(){let[e,t]=(0,c.useState)($[0].id),n=$.find(t=>t.id===e)??$[0];return(0,l.jsxs)(`div`,{className:`max-w-5xl mx-auto p-6 space-y-4`,children:[(0,l.jsxs)(`header`,{children:[(0,l.jsx)(`h1`,{className:`text-2xl font-semibold`,children:`Bedside`}),(0,l.jsx)(`p`,{className:`text-sm text-muted-foreground`,children:`Emergency and rapid-reference pediatric tools. Weight-based dosing throughout — always verify against institutional protocols.`})]}),(0,l.jsx)(`div`,{className:`flex flex-wrap gap-2`,"data-testid":`bedside-subnav`,children:$.map(n=>(0,l.jsxs)(`button`,{type:`button`,onClick:()=>t(n.id),className:`px-3 py-1.5 rounded-full text-xs font-medium border transition-colors `+(e===n.id?`bg-primary text-primary-foreground border-primary`:`bg-muted hover:bg-muted/80 border-border`),"data-testid":`bedside-pill-`+n.id,children:[(0,l.jsx)(`span`,{className:`mr-1`,"aria-hidden":!0,children:n.icon}),n.label]},n.id))}),(0,l.jsx)(ie,{}),te.has(n.id)?ee(n.id):(0,l.jsx)(ae,{pill:n})]})}export{oe as default}; |